

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

10 September 2020 (10.09.2020)



(10) International Publication Number

WO 2020/181207 A1

(51) International Patent Classification:

A61K 31/164 (2006.01) C07C 229/10 (2006.01)

A61K 31/18 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2020/021444

(22) International Filing Date:

06 March 2020 (06.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/814,470 06 March 2019 (06.03.2019) US

(71) Applicant: THE REGENTS OF THE UNIVERSITY

OF MICHIGAN [US/US]; Office of Technology Transfer, 1600 Huron Parkway, 2nd Floor, Ann Arbor, Michigan 48109-2590 (US).

(72) Inventors: NEAMATI, Nouri; c/o The Regents of the Uni-

versity of Michigan, 1600 Huron Parkway, 2nd Floor, Ann Arbor, Michigan 48109-2509 (US). MAO, Shuai; c/o The Regents of the University of Michigan, 1600 Huron Parkway, 2nd Floor, Ann Arbor, Michigan 48109-2590 (US).

(74) Agent: GOETZ, Robert A.; Casimir Jones, S.C., 2275

Deming Way, Ste 310, Middleton, Wisconsin 53562 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE

(57) Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).



WO 2020/181207 A1

SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

5

This invention was made with government support under CA188252 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

10

This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induction of reactive oxygen species. The invention further processes for preparing, and methods for using these compounds to treat cancer (e.g., pancreatic cancer, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer).

15

INTRODUCTION

Cancer is the second leading cause of death in Europe and North America. Surgery, radiation, chemo- and immunotherapies are the major approaches in treating various cancers.

20

Although significant advances have been made during the past decade, the cure rate is still very low for most cancers. Therefore, novel therapeutics is urgently needed to enhance the survival of patients with these devastating diseases. Cancer cells accumulate numerous mutations during the course of their evolution altering multiple signaling pathways and networks. As such, combination of multiple drugs or single compounds having multiple targets tend to show superior activity as compared to single agent drugs. Among various classes of small-molecule drugs tested, quinone containing compounds showed great promise due to their significant increase in oxygen consumption rate in treated cells. Quinones can inhibit various pathways due to their redox, metal-chelation, and in some cases, reactivity toward nucleophiles through Michael addition. Over two dozen drugs containing a quinone moiety have been approved by the FDA or are under clinical investigations not only in oncology but also for other diseases. For example, doxorubicin and dozens of its analogues, mitoxantrone, and mitomycin C are some of the most commonly used FDA approved chemotherapeutic agents for numerous cancers that contain a quinone group.

25

30

Improved small molecule compounds having bicyclic and tetracyclic quinone scaffolds for treating cancer are needed.

The present invention addresses this need.

5 SUMMARY OF THE INVENTION

Altered redox homeostasis in cancer cells provides a new opportunity for tumor intervention. Reactive oxygen species (ROS), a natural by product from mitochondrial respiration, play an important role as second messengers in cell signaling. In tumor cells, antioxidant enzymes are often active as a result of elevated levels of intrinsic ROS. Altered
10 redox homeostasis in tumors make them more susceptible to induced oxidative stress that overwhelms their adaptive antioxidant capacity and triggers ROS-mediated cell death.

Experiments conducted during the course of developing synthesized various new small molecules having bicyclic and tetracyclic quinone scaffolds with improved metabolic stability, solubility, and pharmacokinetic properties. Indeed, as described in Example III,
15 various compounds of the present invention were shown to inhibit the growth of various cancer cell lines (see, Tables 2, 3 4 and 5; Figures 1, 2, 3, 4, and 5).

As such, the present invention provides a new class of small-molecules having a bicyclic and tetracyclic quinone structure which have improved metabolic stability, solubility, and pharmacokinetic properties. The invention further provides uses for such small-molecules
20 as therapeutics for the treatment of cancer.

Accordingly, the present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to therapeutically effective amounts of drug(s) having a bicyclic and tetracyclic quinone structure will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population
25 more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies.


The present invention contemplates that the compounds of the present invention (e.g., compounds having a bicyclic and tetracyclic quinone structure) satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy to induce cell
30 growth inhibition, apoptosis and/or cell cycle arrest in cancer cells, or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the





apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.

In certain embodiments of the invention, combination treatment of animals with a therapeutically effective amount of a compound of the present invention and a course of an anticancer agent produces a greater tumor response and clinical benefit in such animals compared to those treated with the compound or anticancer drugs/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with the present compounds.

Certain compounds having an indole scaffold of the present invention may exist as stereoisomers including optical isomers. The invention includes all stereoisomers, both as pure individual stereoisomer preparations and enriched preparations of each, and both the racemic mixtures of such stereoisomers as well as the individual diastereomers and enantiomers that may be separated according to methods that are well known to those of skill in the art.

In a particular embodiment, compounds having a bicyclic and tetracyclic quinone structure (or similar) encompassed within Formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI and XVII are provided:




**X****XI****XII****XIII****XIV****XV****XVI****XVII**

, including pharmaceutically

5 acceptable salts, solvates, and/or prodrugs thereof.

In some embodiments, R^1 is selected from the group consisting of hydrogen, halo, alkyl, heteroalkyl, optionally substituted C_6 - C_{14} aryl, and optionally substituted 5 to 14 membered heteroaryl.


In some embodiments, R^1 is selected from the group consisting of:



In some embodiments, R^2 is selected from the group consisting of alkyl, optionally substituted C_4 - C_8 cycloalkyl, optionally substituted C_4 - C_8 heteroalkyl, optionally substituted


C4-C8 heterocycloalkyl, optionally substituted C5-C6 aryl, and optionally substituted C4-C6 heteroaryl.

In some embodiments, R^2 is optionally selected from the group consisting of:




- 5 In some embodiments, R^{3a} , R^{3b} , R^{3c} , or R^{3d} is selected from the group consisting of hydrogen, halogen, methyl, methoxy, trifluoromethyl, hydroxyl or cyan.

In some embodiments, R^{3a} , R^{3b} , R^{3c} , or R^{3d} is optionally monosubstituted or polysubstituted selected from the group consisting of:



- 10 In some embodiments, R^4 is selected from the group consisting of alkyl, or heteroalkyl.


In some embodiments, R^4 is optionally selected from the group consisting of:



In some embodiments, A comprises a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

- 15 In some embodiments, X is selected from the group consisting of hydrogen, halogen, amino, heterocycloalkyl, or hydroxyl.

In some embodiments, X is optionally selected from the group consisting of:



In some embodiments, n is an integer selected from 0 to 5.

In some embodiments, m is an integer selected from 0 to 9.










In some embodiments, Y is independently selected from O, S, N atom.










5 In some embodiments, W independently selected from is C atom, N atom.









In some embodiments, compounds shown in Table 1 are contemplated for Formulas I-XVII.





Table 1. Structures of representative compounds contemplated for Formulas I-XVII.






Cpd. No.	Structure	Name
1		7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione
2		7-chloro-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione
3		7-chloro-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
4		5-((7-chloro-5,8-dioxo-5,8-dihydroquinolin-6-yl)amino)-2-(4-methylpiperazin-1-yl)benzonitrile
5		7-chloro-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione









6		7-chloro-6-((4-(piperidin-1-yl)phenyl)amino)quinoline-5,8-dione
7		6-((4-(1H-imidazol-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione
8		7-chloro-6-((4-(pyridin-4-yl)phenyl)amino)quinoline-5,8-dione
9		7-chloro-6-((4-(thiazol-2-yl)phenyl)amino)quinoline-5,8-dione
10		6-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione
11		7-chloro-6-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)quinoline-5,8-dione
12		7-chloro-6-((4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione
13		7-chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione
14		7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methylquinoline-5,8-dione










15		7-chloro-2-methyl-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione
16		5-((7-chloro-2-methyl-5,8-dioxo-5,8-dihydroquinolin-6-yl)amino)-2-(4-methylpiperazin-1-yl)benzonitrile
17		7-chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
18		7-chloro-6-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methylquinoline-5,8-dione
19		7-chloro-6-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione
20		7-chloro-6-((4-morpholino-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
21		7-chloro-6-((4-morpholino-2-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
22		7-chloro-6-((4-(ethylamino)-2-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
23		7-chloro-6-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione

24		7-chloro-6-((4-isopropyl-2-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
25		6-((1H-indol-7-yl)amino)-7-chloroquinoline-5,8-dione
26		6-((4-(4-acetylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)-7-chloroquinoline-5,8-dione
27		7-chloro-6-((4-(ethylamino)-2-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
28		7-chloro-6-((2-fluoro-6-hydroxy-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione
29		7-chloro-6-((4-morpholinophenyl)amino)quinoline-5,8-dione
30		7-chloro-6-((2,3,6-trifluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione
31		(E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide

32		(E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide
33		(E)-4-chloro-N-(4-(4-fluorostyryl)-7-morpholino-5,8-dioxo-5,8-dihydroquinolin-6-yl)butanamide
34		(E)-4-chloro-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)butanamide
35		(E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperazin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide










36		(E)-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)-4-(4-methylpiperazin-1-yl)butanamide
37		(E)-N-(4-(4-fluorostyryl)-5,8-dimethoxyquinolin-6-yl)pentanamide
38		(E)-N-(4-(4-fluorostyryl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide
39		(E)-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)pentanamide
40		(E)-N-(4-(4-fluorostyryl)-7-morpholino-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide





41		(E)-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide
42		9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
43		7-methoxy-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
44		2-methyl-9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile
45		9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile
46		9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-8-carbonitrile
47		9-(4-(methylsulfonyl)piperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile
48		9-(4-ethylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione

49		9-(4-cyclopropylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
50		9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
51		9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
52		2-methyl-9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
53		2-methyl-9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
54		9-(4-cyclopropylpiperazin-1-yl)-2-methylpyrido[2,3-b]phenazine-5,12-dione
55		10-fluoro-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
56		10-chloro-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
57		9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione

58		2-methyl-9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
59		10-chloro-2-methyl-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
60		9-((4-ethylpiperazin-1-yl)methyl)-2-methylpyrido[2,3-b]phenazine-5,12-dione
61		9-(4-methylpiperazine-1-carbonyl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
62		9-morpholino-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
63		9-morpholino-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
64		9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
65		9-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
66		9-morpholino-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione

67		9-(4-(4-hydroxyphenyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
68		9-(4-(tert-butyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
69		9-(4-(4-methoxyphenyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
70		9-((3aS,5S,7aS)-octahydro-7aH-2,5-methanoinden-7a-yl)pyrido[2,3-b]phenazine-5,12-dione
71		9-(thiazol-2-yl)pyrido[2,3-b]phenazine-5,12-dione
72		5,12-dioxo-N,N-dipropyl-5,12-dihydropyrido[2,3-b]phenazine-9-sulfonamide
73		9-cyclopropylpyrido[2,3-b]phenazine-5,12-dione
74		9-cyclohexylpyrido[2,3-b]phenazine-5,12-dione
75		9-((2-(diethylamino)ethyl)amino)pyrido[2,3-b]phenazine-5,12-dione

76		2-(4-methylpiperazin-1-yl)benzo[b]phenazine-6,11-dione
77		2-(4-(tert-butyl)piperazin-1-yl)benzo[b]phenazine-6,11-dione
78		9-(1-methylpiperidin-4-yl)pyrido[2,3-b]phenazine-5,12-dione
79		9-(4-methyl-1,4-diazepan-1-yl)pyrido[2,3-b]phenazine-5,12-dione
80		9-(pyrrolidin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
81		9-(pyrrolidin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
82		10-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
83		8-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
84		9-(4-acetyl-1-piperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione

85		9-(4-acetylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione
86		9-morpholinopyrido[2,3-b]phenazine-5,12-dione
87		7-methyl-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione
88		9-isopropylpyrido[2,3-b]phenazine-5,12-dione

In some embodiments, any of the compounds described herein are 2,2,2-trifluoroacetate (TFA) salts.

The invention further provides processes for preparing any of the compounds of the present invention through following at least a portion of the techniques recited in the Experimental Section.

The invention also provides the use of the compounds to induce cell cycle arrest and/or apoptosis in cancer cells. The invention also relates to the use of compounds for sensitizing cells to additional agent(s), such as inducers of apoptosis and/or cell cycle arrest, and chemoprotection of normal cells through the induction of cell cycle arrest prior to treatment with chemotherapeutic agents.

The compounds of the invention are useful for the treatment, amelioration, or prevention of disorders, such as those responsive to induction of apoptotic cell death, e.g., disorders characterized by dysregulation of apoptosis, including hyperproliferative diseases such as cancer. In certain embodiments, the compounds can be used to treat, ameliorate, or prevent cancer that is characterized by resistance to cancer therapies (e.g., those cancer cells which are chemoresistant, radiation resistant, hormone resistant, and the like). In certain embodiments, the cancer is multiple myeloma, acute myeloid leukemia, melanoma, breast

cancer, head or neck cancers, colon cancer, lung cancer, ovarian cancer, prostate cancer, and/or pancreatic cancer.

The invention also provides pharmaceutical compositions comprising the compounds of the invention in a pharmaceutically acceptable carrier.

5 The invention also provides kits comprising a compound of the invention and instructions for administering the compound to an animal. The kits may optionally contain other therapeutic agents, e.g., anticancer agents or apoptosis-modulating agents.

BRIEF DESCRIPTION OF DRAWINGS

- 10 FIG. 1: Growth inhibition (% control) of compound **1** in the NCI60 cell lines.
FIG. 2: Growth inhibition (% control) of compound **13** in the NCI60 cell lines.
FIG. 3: Growth inhibition (% control) of compound **49** in the NCI60 cell lines.
FIG. 4: Growth inhibition (% control) of compound **50** in the NCI60 cell lines.
FIG. 5: Cytotoxicity of compound **13** in the NCI60 cell lines.

15

DEFINITIONS

The term “anticancer agent” as used herein, refer to any therapeutic agents (*e.g.*, chemotherapeutic compounds and/or molecular therapeutic compounds), antisense therapies, radiation therapies, or surgical interventions, used in the treatment of hyperproliferative
20 diseases such as cancer (*e.g.*, in mammals, *e.g.*, in humans).

The term “prodrug” as used herein, refers to a pharmacologically inactive derivative of a parent “drug” molecule that requires biotransformation (*e.g.*, either spontaneous or enzymatic) within the target physiological system to release, or to convert (*e.g.*, enzymatically, physiologically, mechanically, electromagnetically) the prodrug into the active
25 drug. Prodrugs are designed to overcome problems associated with stability, water solubility, toxicity, lack of specificity, or limited bioavailability. Exemplary prodrugs comprise an active drug molecule itself and a chemical masking group (*e.g.*, a group that reversibly suppresses the activity of the drug). Some prodrugs are variations or derivatives of compounds that have groups cleavable under metabolic conditions. Prodrugs can be readily prepared from the
30 parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: "Design and Applications of Prodrugs"; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery,

K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985, particularly pp. 309-396; Burger's Medicinal Chemistry and Drug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975; and Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier, 1987.

Exemplary prodrugs become pharmaceutically active *in vivo* or *in vitro* when they undergo solvolysis under physiological conditions or undergo enzymatic degradation or other biochemical transformation (*e.g.*, phosphorylation, hydrogenation, dehydrogenation, glycosylation). Prodrugs often offer advantages of water solubility, tissue compatibility, or delayed release in the mammalian organism. (*See e.g.*, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA (1992)). Common prodrugs include acid derivatives such as esters prepared by reaction of parent acids with a suitable alcohol (*e.g.*, a lower alkanol) or esters prepared by reaction of parent alcohol with a suitable carboxylic acid, (*e.g.*, an amino acid), amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base derivative (*e.g.*, a lower alkylamide), or phosphorus-containing derivatives, *e.g.*, phosphate, phosphonate, and phosphoramidate esters, including cyclic phosphate, phosphonate, and phosphoramidate (*see, e.g.*, US Patent Application Publication No. US 2007/0249564 A1; herein incorporated by reference in its entirety).

The term "pharmaceutically acceptable salt" as used herein, refers to any salt (*e.g.*, obtained by reaction with an acid or a base) of a compound of the present invention that is physiologically tolerated in the target animal (*e.g.*, a mammal). Salts of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Examples of bases include, but are not limited to, alkali metal (*e.g.*, sodium) hydroxides, alkaline earth metal (*e.g.*, magnesium) hydroxides, ammonia, and compounds of formula NW_4^+ , wherein W is C₁₋₄ alkyl, and the like.

Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, lactate, maleate, mesylate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the present invention compounded with a suitable cation such as Na^+ , NH_4^+ , and NW_4^+ (wherein W is a C₁₋₄ alkyl group), and the like. For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

The term "solvate" as used herein, refers to the physical association of a compound of the invention with one or more solvent molecules, whether organic or inorganic. This physical association often includes hydrogen bonding. In certain instances, the solvate is capable of isolation, for example, when one or more solvate molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanolates, and methanolates.

The term "therapeutically effective amount," as used herein, refers to that amount of the therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder, or prevent advancement of a disorder, or cause regression of the disorder. For example, with respect to the treatment of cancer, in one embodiment, a therapeutically effective amount will refer to the amount of a therapeutic agent that decreases the rate of tumor growth, decreases tumor mass, decreases the number of metastases, increases time to tumor progression, or increases survival time by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.

The terms “sensitize” and “sensitizing,” as used herein, refer to making, through the administration of a first agent (*e.g.*, a benzoic acid compound of the invention), an animal or a cell within an animal more susceptible, or more responsive, to the biological effects (*e.g.*, promotion or retardation of an aspect of cellular function including, but not limited to, cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis) of a second agent. The sensitizing effect of a first agent on a target cell can be measured as the difference in the intended biological effect (*e.g.*, promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis) observed upon the administration of a second agent with and without administration of the first agent. The response of the sensitized cell can be increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least 300%, at least about 350%, at least about 400%, at least about 450%, or at least about 500% over the response in the absence of the first agent.

The term “dysregulation of apoptosis,” as used herein, refers to any aberration in the ability of (*e.g.*, predisposition) a cell to undergo cell death via apoptosis. Dysregulation of apoptosis is associated with or induced by a variety of conditions, non-limiting examples of which include, autoimmune disorders (*e.g.*, systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, or Sjögren's syndrome), chronic inflammatory conditions (*e.g.*, psoriasis, asthma or Crohn's disease), hyperproliferative disorders (*e.g.*, tumors, B cell lymphomas, or T cell lymphomas), viral infections (*e.g.*, herpes, papilloma, or HIV), and other conditions such as osteoarthritis and atherosclerosis.

The term “hyperproliferative disease,” as used herein, refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth. Examples of hyperproliferative disorders include tumors, neoplasms, lymphomas and the like. A neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these. A “metastatic” cell means that the cell can invade and destroy neighboring body structures. Hyperplasia is a form of cell proliferation involving an increase in cell number in a tissue or organ without significant alteration in structure or function. Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell.

The pathological growth of activated lymphoid cells often results in an autoimmune disorder or a chronic inflammatory condition. As used herein, the term “autoimmune disorder” refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues. Non-limiting examples of autoimmune disorders include autoimmune hemolytic anemia, autoimmune hepatitis, Berger’s disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn’s disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave’s disease, Hashimoto’s thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjögren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, and the like.

The term “neoplastic disease,” as used herein, refers to any abnormal growth of cells being either benign (non-cancerous) or malignant (cancerous).

The term "normal cell," as used herein, refers to a cell that is not undergoing abnormal growth or division. Normal cells are non-cancerous and are not part of any hyperproliferative disease or disorder.

The term “anti-neoplastic agent,” as used herein, refers to any compound that retards the proliferation, growth, or spread of a targeted (*e.g.*, malignant) neoplasm.

The terms “prevent,” “preventing,” and “prevention,” as used herein, refer to a decrease in the occurrence of pathological cells (*e.g.*, hyperproliferative or neoplastic cells) in an animal. The prevention may be complete, *e.g.*, the total absence of pathological cells in a subject. The prevention may also be partial, such that the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention.

The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable vehicle" encompasses any of the standard pharmaceutical carriers, solvents, surfactants, or vehicles. Suitable pharmaceutically acceptable vehicles include aqueous vehicles and nonaqueous vehicles. Standard pharmaceutical carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.


DETAILED DESCRIPTION OF THE INVENTION

Experiments conducted during the course of developing synthesized various new small molecules having bicyclic and tetracyclic quinone scaffolds with improved metabolic stability, solubility, and pharmacokinetic properties. Indeed, as described in Example III,


various compounds of the present invention were shown to inhibit the growth of various cancer cell lines (see, Tables 2, 3, 4 and 5; Figures 1, 2, 3, 4, and 5).

As such, the present invention provides a new class of small-molecules having a bicyclic and tetracyclic quinone structure which have improved metabolic stability, solubility, and pharmacokinetic properties. The invention further provides uses for such small-molecules as therapeutics for the treatment of cancer.


In a particular embodiment, compounds having a bicyclic and tetracyclic quinone structure (or similar) encompassed within Formulas I, II, III, IV, V, VI, VII, VIII, IX, X XI, XII, XIII, XIV, XV, XVI and XVII are provided:




I




II




III




IV




V




VI




VII




VIII









IX



X



XI


**XII****XIII****XIV****XV****XVI****XVII**

, including pharmaceutically

acceptable salts, solvates, and/or prodrugs thereof.


- 5 In some embodiments, R^1 is selected from the group consisting of hydrogen, halo, alkyl, heteroalkyl, optionally substituted C_6 - C_{14} aryl, and optionally substituted 5 to 14 membered heteroaryl.

In some embodiments, R^1 is selected from the group consisting of:




- 10 In some embodiments, R^2 is selected from the group consisting of alkyl, optionally substituted C_4 - C_8 cycloalkyl, optionally substituted C_4 - C_8 heteroalkyl, optionally substituted C_4 - C_8 heterocycloalkyl, optionally substituted C_5 - C_6 aryl, and optionally substituted C_4 - C_6 heteroaryl.

In some embodiments, R^2 is optionally selected from the group consisting of:




In some embodiments, R^{3a} , R^{3b} , R^{3c} , or R^{3d} is selected from the group consisting of hydrogen, halogen, methyl, methoxy, trifluoromethyl, hydroxyl or cyan.

In some embodiments, R^{3a} , R^{3b} , R^{3c} , or R^{3d} is optionally monosubstituted or
5 polysubstituted selected from the group consisting of:



In some embodiments, R^4 is selected from the group consisting of alkyl, or heteroalkyl.

In some embodiments, R^4 is optionally selected from the group consisting of:




10

In some embodiments, A comprises a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.

In some embodiments, X is selected from the group consisting of hydrogen, halogen, amino, heterocycloalkyl, or hydroxyl.

In some embodiments, X is optionally selected from the group consisting of:



15

In some embodiments, n is an integer selected from 0 to 5.

In some embodiments, m is an integer selected from 0 to 9.

In some embodiments, Y is independently selected from O, S, N atom.

In some embodiments, W independently selected from is C atom, N atom.

5 In some embodiments, compounds shown in Table 1 are contemplated for Formulas I-XVII.

In some embodiments, compounds shown in Table 1 are contemplated for Formula I.

An important aspect of the present invention is that compounds of the invention induce cell cycle arrest and/or apoptosis and also potentiate the induction of cell cycle arrest
10 and/or apoptosis either alone or in response to additional apoptosis induction signals. Therefore, it is contemplated that these compounds sensitize cells to induction of cell cycle arrest and/or apoptosis, including cells that are resistant to such inducing stimuli. The compounds of the present invention (e.g., indole (or similar) compounds) can be used to induce apoptosis in any disorder that can be treated, ameliorated, or prevented by the
15 induction of apoptosis. In one embodiment, the modulators (e.g., inhibitors) can be used to induce apoptosis in cells through induction of reactive oxygen species in the relevant cell(s).

In some embodiments, the compositions and methods of the present invention are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g., a mammalian patient including, but not limited to, humans and veterinary
20 animals). In this regard, various diseases and pathologies are amenable to treatment or prophylaxis using the present methods and compositions. A non-limiting exemplary list of these diseases and conditions includes, but is not limited to, pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head and neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck
25 carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant
30 pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia,

chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma, and the like, T and B cell mediated autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative conditions, vascular diseases, and the like. In some embodiments, the cancer cells being treated are metastatic. In other embodiments, the cancer cells being treated are resistant to anticancer agents.

Some embodiments of the present invention provide methods for administering an effective amount of a compound of the invention and at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (*e.g.*, surgical intervention, and/or radiotherapies). In a particular embodiment, the additional therapeutic agent(s) is an anticancer agent.

A number of suitable anticancer agents are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (*e.g.*, anti-sense, ribozymes, siRNA); polypeptides (*e.g.*, enzymes and antibodies); biological mimetics; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal or polyclonal antibodies (*e.g.*, antibodies conjugated with anticancer drugs, toxins, defensins), toxins; radionuclides; biological response modifiers (*e.g.*, interferons (*e.g.*, IFN- α) and interleukins (*e.g.*, IL-2)); adoptive immunotherapy agents; hematopoietic growth factors; agents that induce tumor cell differentiation (*e.g.*, all-trans-retinoic acid); gene therapy reagents (*e.g.*, antisense therapy reagents and nucleotides); tumor vaccines; angiogenesis inhibitors; proteasome inhibitors; NF-KB modulators; anti-CDK compounds; HDAC inhibitors; and the like. Numerous other examples of chemotherapeutic compounds and anticancer therapies suitable for co-administration with the disclosed compounds are known to those skilled in the art.

In certain embodiments, anticancer agents comprise agents that induce or stimulate apoptosis. Agents that induce apoptosis include, but are not limited to, radiation (*e.g.*, X-rays, gamma rays, UV); tumor necrosis factor (TNF)-related factors (*e.g.*, TNF family receptor proteins, TNF family ligands, TRAIL, antibodies to TRAIL-R1 or TRAIL-R2); kinase inhibitors (*e.g.*, epidermal growth factor receptor (EGFR) kinase inhibitor, vascular growth

factor receptor (VGFR) kinase inhibitor, fibroblast growth factor receptor (FGFR) kinase inhibitor, platelet-derived growth factor receptor (PDGFR) kinase inhibitor, and Bcr-Abl kinase inhibitors (such as GLEEVEC)); antisense molecules; antibodies (*e.g.*, HERCEPTIN, RITUXAN, ZEVALIN, and AVASTIN); anti-estrogens (*e.g.*, raloxifene and tamoxifen); anti-androgens (*e.g.*, flutamide, bicalutamide, finasteride, aminoglutethamide, ketoconazole, and corticosteroids); cyclooxygenase 2 (COX-2) inhibitors (*e.g.*, celecoxib, meloxicam, NS-398, and non-steroidal anti-inflammatory drugs (NSAIDs)); anti-inflammatory drugs (*e.g.*, butazolidin, DECADRON, DELTASONE, dexamethasone, dexamethasone intensol, DEXONE, HEXADROL, hydroxychloroquine, METICORTEN, ORADEXON, ORASONE, oxyphenbutazone, PEDIAPRED, phenylbutazone, PLAQUENIL, prednisolone, prednisone, PRELONE, and TANDEARIL); and cancer chemotherapeutic drugs (*e.g.*, irinotecan (CAMPTOSAR), CPT-11, fludarabine (FLUDARA), dacarbazine (DTIC), dexamethasone, mitoxantrone, MYLOTARG, VP-16, cisplatin, carboplatin, oxaliplatin, 5-FU, doxorubicin, gemcitabine, bortezomib, gefitinib, bevacizumab, TAXOTERE or TAXOL); cellular signaling molecules; ceramides and cytokines; staurosporine, and the like.

In still other embodiments, the compositions and methods of the present invention provide a compound of the invention and at least one anti-hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (*e.g.*, herbs and other plant and/or animal derived compounds).

Alkylating agents suitable for use in the present compositions and methods include, but are not limited to: 1) nitrogen mustards (*e.g.*, mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil); 2) ethylenimines and methylmelamines (*e.g.*, hexamethylmelamine and thiotepa); 3) alkyl sulfonates (*e.g.*, busulfan); 4) nitrosoureas (*e.g.*, carmustine (BCNU); lomustine (CCNU); semustine (methyl-CCNU); and streptozocin (streptozotocin)); and 5) triazenes (*e.g.*, dacarbazine (DTIC); dimethyltriazenoimid-azolecarboxamide).

In some embodiments, antimetabolites suitable for use in the present compositions and methods include, but are not limited to: 1) folic acid analogs (*e.g.*, methotrexate (amethopterin)); 2) pyrimidine analogs (*e.g.*, fluorouracil (5-fluorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytarabine (cytosine arabinoside)); and 3) purine analogs (*e.g.*, mercaptopurine (6-mercaptopurine; 6-MP), thioguanine (6-thioguanine; TG), and pentostatin (2'-deoxycoformycin)).

In still further embodiments, chemotherapeutic agents suitable for use in the compositions and methods of the present invention include, but are not limited to: 1) vinca alkaloids (*e.g.*, vinblastine (VLB), vincristine); 2) epipodophyllotoxins (*e.g.*, etoposide and teniposide); 3) antibiotics (*e.g.*, dactinomycin (actinomycin D), daunorubicin (daunomycin; 5 rubidomycin), doxorubicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (*e.g.*, L-asparaginase); 5) biological response modifiers (*e.g.*, interferon-alfa); 6) platinum coordinating complexes (*e.g.*, cisplatin (cis-DDP) and carboplatin); 7) anthracenediones (*e.g.*, mitoxantrone); 8) substituted ureas (*e.g.*, hydroxyurea); 9) methylhydrazine derivatives (*e.g.*, procarbazine (N-methylhydrazine; 10 MIH)); 10) adrenocortical suppressants (*e.g.*, mitotane (o,p'-DDD) and aminoglutethimide); 11) adrenocorticosteroids (*e.g.*, prednisone); 12) progestins (*e.g.*, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate); 13) estrogens (*e.g.*, diethylstilbestrol and ethinyl estradiol); 14) antiestrogens (*e.g.*, tamoxifen); 15) androgens (*e.g.*, testosterone propionate and fluoxymesterone); 16) antiandrogens (*e.g.*, flutamide); and 15 17) gonadotropin-releasing hormone analogs (*e.g.*, leuprolide).

Any oncolytic agent that is routinely used in a cancer therapy context finds use in the compositions and methods of the present invention. For example, the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States. International counterpart agencies to the U.S.F.D.A. maintain similar formularies. 20 Table 6 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.

Table 6

Aldesleukin (des-alanyl-1, serine-125 human interleukin-2)	Proleukin	Chiron Corp., Emeryville, CA
Alemtuzumab (IgG1κ anti CD52 antibody)	Campath	Millennium and ILEX Partners, LP, Cambridge, MA
Alitretinoin (9-cis-retinoic acid)	Panretin	Ligand Pharmaceuticals, Inc., San Diego CA
Allopurinol (1,5-dihydro-4 H -pyrazolo[3,4-d]pyrimidin-4-one monosodium salt)	Zyloprim	GlaxoSmithKline, Research Triangle Park, NC
Altretamine	Hexalen	US Bioscience, West

(N,N,N',N',N'',N'',- hexamethyl-1,3,5-triazine-2, 4, 6-triamine)		Conshohocken, PA
Amifostine (ethanethiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester))	Ethiol	US Bioscience
Anastrozole (1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl))	Arimidex	AstraZeneca Pharmaceuticals, LP, Wilmington, DE
Arsenic trioxide	Trisenox	Cell Therapeutic, Inc., Seattle, WA
Asparaginase (L-asparagine amidohydrolase, type EC-2)	Elspar	Merck & Co., Inc., Whitehouse Station, NJ
BCG Live (lyophilized preparation of an attenuated strain of <i>Mycobacterium bovis</i> (<i>Bacillus Calmette-Guérin</i> [BCG], substrain Montreal)	TICE BCG	Organon Teknika, Corp., Durham, NC
bexarotene capsules (4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl] benzoic acid)	Targretin	Ligand Pharmaceuticals
bexarotene gel	Targretin	Ligand Pharmaceuticals
Bleomycin (cytotoxic glycopeptide antibiotics produced by <i>Streptomyces verticillus</i> ; bleomycin A ₂ and bleomycin B ₂)	Blenoxane	Bristol-Myers Squibb Co., NY, NY
Capecitabine (5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine)	Xeloda	Roche
Carboplatin (platinum, diammine [1,1-cyclobutanedicarboxylato(2-)-0, 0']-, (SP-4-2))	Paraplatin	Bristol-Myers Squibb
Carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea)	BCNU, BiCNU	Bristol-Myers Squibb
Carmustine with Polifeprosan 20 Implant	Gliadel Wafer	Guilford Pharmaceuticals, Inc., Baltimore, MD
Celecoxib (as 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide)	Celebrex	Searle Pharmaceuticals, England
Chlorambucil (4-[bis(2chloroethyl)amino]benzenebutanoic acid)	Leukeran	GlaxoSmithKline
Cisplatin (PtCl ₂ H ₆ N ₂)	Platinol	Bristol-Myers Squibb
Cladribine (2-chloro-2'-deoxy-b-D-adenosine)	Leustatin, 2-CdA	R.W. Johnson Pharmaceutical Research Institute,

		Raritan, NJ
Cyclophosphamide (2-[bis(2-chloroethyl)amino] tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate)	Cytosan, Neosar	Bristol-Myers Squibb
Cytarabine (1-β-D-Arabinofuranosylcytosine, C ₉ H ₁₃ N ₃ O ₅)	Cytosar-U	Pharmacia & Upjohn Company
cytarabine liposomal	DepoCyt	Skye Pharmaceuticals, Inc., San Diego, CA
Dacarbazine (5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC))	DTIC-Dome	Bayer AG, Leverkusen, Germany
Dactinomycin, actinomycin D (actinomycin produced by <i>Streptomyces parvullus</i> , C ₆₂ H ₈₆ N ₁₂ O ₁₆)	Cosmegen	Merck
Darbepoetin alfa (recombinant peptide)	Aranesp	Amgen, Inc., Thousand Oaks, CA
daunorubicin liposomal ((8S-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride)	DanuoXome	Nexstar Pharmaceuticals, Inc., Boulder, CO
Daunorubicin HCl, daunomycin ((1 S, 3 S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-(α)-L-lyxo-hexopyranoside hydrochloride)	Cerubidine	Wyeth Ayerst, Madison, NJ
Denileukin diftitox (recombinant peptide)	Ontak	Seragen, Inc., Hopkinton, MA
Dexrazoxane ((S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione)	Zinecard	Pharmacia & Upjohn Company
Docetaxel ((2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5b-20-epoxy-12a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate)	Taxotere	Aventis Pharmaceuticals, Inc., Bridgewater, NJ
Doxorubicin HCl (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride)	Adriamycin, Rubex	Pharmacia & Upjohn Company
doxorubicin	Adriamycin PFS Intravenous injection	Pharmacia & Upjohn Company
doxorubicin liposomal	Doxil	Sequus Pharmaceuticals, Inc., Menlo park, CA
dromostanolone propionate	Dromostanolone	Eli Lilly & Company,

(17b-Hydroxy-2a-methyl-5a-androstan-3-one propionate)		Indianapolis, IN
dromostanolone propionate	Masterone injection	Syntex, Corp., Palo Alto, CA
Elliott's B Solution	Elliott's B Solution	Orphan Medical, Inc
Epirubicin ((8S-cis)-10-[(3-amino-2,3,6-trideoxy-a-L-arabino- hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride)	Ellence	Pharmacia & Upjohn Company
Epoetin alfa (recombinant peptide)	Epogen	Amgen, Inc
Estramustine (estra-1,3,5(10)-triene-3,17-diol(17(beta))-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate, or estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate)	Emcyt	Pharmacia & Upjohn Company
Etoposide phosphate (4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-(beta)-D-glucopyranoside], 4'-(dihydrogen phosphate))	Etopophos	Bristol-Myers Squibb
etoposide, VP-16 (4'-demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-(beta)-D-glucopyranoside])	Vepesid	Bristol-Myers Squibb
Exemestane (6-methylenandrosta-1,4-diene-3, 17-dione)	Aromasin	Pharmacia & Upjohn Company
Filgrastim (r-metHuG-CSF)	Neupogen	Amgen, Inc
floxuridine (intraarterial) (2'-deoxy-5-fluorouridine)	FUDR	Roche
Fludarabine (fluorinated nucleotide analog of the antiviral agent vidarabine, 9-b -D-arabinofuranosyladenine (ara-A))	Fludara	Berlex Laboratories, Inc., Cedar Knolls, NJ
Fluorouracil, 5-FU (5-fluoro-2,4(1H,3H)-pyrimidinedione)	Adrucil	ICN Pharmaceuticals, Inc., Humacao, Puerto Rico
Fulvestrant (7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphonyl) nonyl]estra-1,3,5-(10)-triene-3,17-beta-diol)	Faslodex	IPR Pharmaceuticals, Guayama, Puerto Rico
Gemcitabine (2'-deoxy-2', 2'-difluorocytidine monohydrochloride (b-isomer))	Gemzar	Eli Lilly

Gemtuzumab Ozogamicin (anti-CD33 hP67.6)	Mylotarg	Wyeth Ayerst
Goserelin acetate	Zoladex Implant	AstraZeneca Pharmaceuticals
Hydroxyurea	Hydrea	Bristol-Myers Squibb
Ibritumomab Tiuxetan (immunoconjugate resulting from a thiourea covalent bond between the monoclonal antibody Ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine)	Zevalin	Biogen IDEC, Inc., Cambridge MA
Idarubicin (5, 12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-(alpha)-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis))	Idamycin	Pharmacia & Upjohn Company
Ifosfamide (3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide)	IFEX	Bristol-Myers Squibb
Imatinib Mesilate (4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate)	Gleevec	Novartis AG, Basel, Switzerland
Interferon alfa-2a (recombinant peptide)	Roferon-A	Hoffmann-La Roche, Inc., Nutley, NJ
Interferon alfa-2b (recombinant peptide)	Intron A (Lyophilized Betaseron)	Schering AG, Berlin, Germany
Irinotecan HCl (((4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione hydrochloride trihydrate)	Camptosar	Pharmacia & Upjohn Company
Letrozole (4,4'-(1H-1,2,4-Triazol-1-yl)methylene)dibenzonitrile)	Femara	Novartis
Leucovorin (L-Glutamic acid, N[4[[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridiny]methyl]amino]benzoyl], calcium salt (1:1))	Wellcovorin, Leucovorin	Immunex, Corp., Seattle, WA
Levamisole HCl ((-)-(S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole monohydrochloride)	Ergamisol	Janssen Research Foundation, Titusville, NJ

C ₁₁ H ₁₂ N ₂ S·HCl)		
Lomustine (1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea)	CeeNU	Bristol-Myers Squibb
Meclorethamine, nitrogen mustard (2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride)	Mustargen	Merck
Megestrol acetate 17 α (acetyloxy)- 6- methylpregna- 4,6- diene- 3,20- dione	Megace	Bristol-Myers Squibb
Melphalan, L-PAM (4-[bis(2-chloroethyl) amino]-L-phenylalanine)	Alkeran	GlaxoSmithKline
Mercaptopurine, 6-MP (1,7-dihydro-6 H -purine-6-thione monohydrate)	Purinethol	GlaxoSmithKline
Mesna (sodium 2-mercaptoethane sulfonate)	Mesnex	Asta Medica
Methotrexate (N-[4-[[[(2,4-diamino-6-pteridiny]methyl)methylamino]benzoyl]-L-glutamic acid)	Methotrexate	Lederle Laboratories
Methoxsalen (9-methoxy-7H-furo[3,2-g][1]-benzopyran-7-one)	Uvadex	Therakos, Inc., Way Exton, Pa
Mitomycin C	Mutamycin	Bristol-Myers Squibb
mitomycin C	Mitozytrex	SuperGen, Inc., Dublin, CA
Mitotane (1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane)	Lysodren	Bristol-Myers Squibb
Mitoxantrone (1,4-dihydroxy-5,8-bis[[2- [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride)	Novantrone	Immunex Corporation
Nandrolone phenpropionate	Durabolin-50	Organon, Inc., West Orange, NJ
Nofetumomab	Verluma	Boehringer Ingelheim Pharma KG, Germany
Oprelvekin (IL-11)	Neumega	Genetics Institute, Inc., Alexandria, VA
Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)-O,O'] platinum)	Eloxatin	Sanofi Synthelabo, Inc., NY, NY
Paclitaxel (5 β , 20-Epoxy-1,2a, 4,7 β , 10 β , 13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3 S)- N-benzoyl-3-phenylisoserine)	TAXOL	Bristol-Myers Squibb

Pamidronate (phosphonic acid (3-amino-1-hydroxypropylidene) bis-, disodium salt, pentahydrate, (APD))	Aredia	Novartis
Pegademase ((monomethoxypolyethylene glycol succinimidyl) 11 - 17 -adenosine deaminase)	Adagen (Pegademase Bovine)	Enzon Pharmaceuticals, Inc., Bridgewater, NJ
Pegaspargase (monomethoxypolyethylene glycol succinimidyl L-asparaginase)	Oncaspar	Enzon
Pegfilgrastim (covalent conjugate of recombinant methionyl human G-CSF (Filgrastim) and monomethoxypolyethylene glycol)	Neulasta	Amgen, Inc
Pentostatin	Nipent	Parke-Davis Pharmaceutical Co., Rockville, MD
Pipobroman	Vercyte	Abbott Laboratories, Abbott Park, IL
Plicamycin, Mithramycin (antibiotic produced by <i>Streptomyces plicatus</i>)	Mithracin	Pfizer, Inc., NY, NY
Porfimer sodium	Photofrin	QLT Phototherapeutics, Inc., Vancouver, Canada
Procarbazine (N-isopropyl-μ-(2-methylhydrazino)-p-tolamide monohydrochloride)	Matulane	Sigma Tau Pharmaceuticals, Inc., Gaithersburg, MD
Quinacrine (6-chloro-9-(1-methyl-4-diethyl-amine) butylamino-2-methoxyacridine)	Atabrine	Abbott Labs
Rasburicase (recombinant peptide)	Elitek	Sanofi-Synthelabo, Inc.,
Rituximab (recombinant anti-CD20 antibody)	Rituxan	Genentech, Inc., South San Francisco, CA
Sargramostim (recombinant peptide)	Prokine	Immunex Corp
Streptozocin (streptozocin 2-deoxy-2-[[[(methylnitrosoamino)carbonyl]amino]-a (and b)-D-glucopyranose and 220 mg citric acid anhydrous])	Zanosar	Pharmacia & Upjohn Company
Talc (Mg ₃ Si ₄ O ₁₀ (OH) ₂)	Sclerosol	Bryan, Corp., Woburn, MA
Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (1:1))	Nolvadex	AstraZeneca Pharmaceuticals
Temozolomide	Temodar	Schering

(3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide)		
teniposide, VM-26 (4'-demethylepipodophyllotoxin 9-[4,6-O-(R)-2-thenylidene-(beta)-D-glucopyranoside])	Vumon	Bristol-Myers Squibb
Testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid [dgr]-lactone)	Teslac	Bristol-Myers Squibb
Thioguanine, 6-TG (2-amino-1,7-dihydro-6H-purine-6-thione)	Thioguanine	GlaxoSmithKline
Thiotepa (Aziridine, 1,1',1''-phosphinothioylidynetris-, or Tris (1-aziridiny) phosphine sulfide)	Thiopex	Immunex Corporation
Topotecan HCl (S)-10-[(dimethylamino) methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione monohydrochloride)	Hycamtin	GlaxoSmithKline
Toremifene (2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethylethylamine citrate (1:1))	Fareston	Roberts Pharmaceutical Corp., Eatontown, NJ
Tositumomab, I 131 Tositumomab (recombinant murine immunotherapeutic monoclonal IgG _{2a} lambda anti-CD20 antibody (I 131 is a radioimmunotherapeutic antibody))	Bexxar	Corixa Corp., Seattle, WA
Trastuzumab (recombinant monoclonal IgG ₁ kappa anti-HER2 antibody)	Herceptin	Genentech, Inc
Tretinoin, ATRA (all-trans retinoic acid)	Vesanoid	Roche
Uracil Mustard	Uracil Mustard Capsules	Roberts Labs
Valrubicin, N-trifluoroacetyladiamycin-14-valerate (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-[[4,2,3,6-trideoxy-3-[(trifluoroacetyl)-amino-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl pentanoate)	Valstar	Anthra --> Medeva
Vinblastine, Leurocristine (C ₄₆ H ₅₆ N ₄ O ₁₀ •H ₂ SO ₄)	Velban	Eli Lilly
Vincristine (C ₄₆ H ₅₆ N ₄ O ₁₀ •H ₂ SO ₄)	Oncovin	Eli Lilly
Vinorelbine (3',4'-didehydro-4'-deoxy-C'-	Navelbine	GlaxoSmithKline

norvincaleukoblastine [R-(R*,R*)-2,3-dihydroxybutanedioate (1:2)(salt)]		
Zoledronate, Zoledronic acid ((1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate)	Zometa	Novartis

Anticancer agents further include compounds which have been identified to have anticancer activity. Examples include, but are not limited to, 3-AP, 12-O-tetradecanoylphorbol-13-acetate, 17AAG, 852A, ABI-007, ABR-217620, ABT-751, ADI-PEG 20, AE-941, AG-013736, AGRO100, alanosine, AMG 706, antibody G250, antineoplastons, AP23573, apaziquone, APC8015, atiprimod, ATN-161, atrasenten, azacitidine, BB-10901, BCX-1777, bevacizumab, BG00001, bicalutamide, BMS 247550, bortezomib, bryostatin-1, buserelin, calcitriol, CCI-779, CDB-2914, cefixime, cetuximab, CG0070, cilengitide, clofarabine, combretastatin A4 phosphate, CP-675,206, CP-724,714, CpG 7909, curcumin, decitabine, DENSPM, doxercalciferol, E7070, E7389, ecteinascidin 743, efaproxiral, eflornithine, EKB-569, enzastaurin, erlotinib, exisulind, fenretinide, flavopiridol, fludarabine, flutamide, fotemustine, FR901228, G17DT, galiximab, gefitinib, genistein, glufosfamide, GTI-2040, histrelin, HKI-272, homoharringtonine, HSPPC-96, hu14.18-interleukin-2 fusion protein, HuMax-CD4, iloprost, imiquimod, infliximab, interleukin-12, IPI-504, irofulven, ixabepilone, lapatinib, lenalidomide, lestaurtinib, leuprolide, LMB-9 immunotoxin, lonafarnib, luniliximab, mafosfamide, MB07133, MDX-010, MLN2704, monoclonal antibody 3F8, monoclonal antibody J591, motexafin, MS-275, MVA-MUC1-IL2, nilutamide, nitrocamptothecin, nolatrexed dihydrochloride, nolvadex, NS-9, O6-benzylguanine, oblimersen sodium, ONYX-015, oregovomab, OSI-774, panitumumab, paraplatin, PD-0325901, pemetrexed, PHY906, pioglitazone, pirfenidone, pixantrone, PS-341, PSC 833, PXD101, pyrazoloacridine, R115777, RAD001, ranpirnase, rebeccamycin analogue, rhuAngiostatin protein, rhuMab 2C4, rosiglitazone, rubitecan, S-1, S-8184, satraplatin, SB-, 15992, SGN-0010, SGN-40, sorafenib, SR31747A, ST1571, SU011248, suberoylanilide hydroxamic acid, suramin, talabostat, talampanel, tariquidar, temsirolimus, TGFa-PE38 immunotoxin, thalidomide, thymalfasin, tipifarnib, tirapazamine, TLK286, trabectedin, trimetrexate glucuronate, TroVax, UCN-1, valproic acid, vinflunine, VNP40101M, volociximab, vorinostat, VX-680, ZD1839, ZD6474, zileuton, and zosuquidar trihydrochloride.

For a more detailed description of anticancer agents and other therapeutic agents, those skilled in the art are referred to any number of instructive manuals including, but not

limited to, the Physician's Desk Reference and to Goodman and Gilman's "Pharmaceutical Basis of Therapeutics" tenth edition, Eds. Hardman *et al.*, 2002.

The present invention provides methods for administering a compound of the invention with radiation therapy. The invention is not limited by the types, amounts, or delivery and administration systems used to deliver the therapeutic dose of radiation to an animal. For example, the animal may receive photon radiotherapy, particle beam radiation therapy, other types of radiotherapies, and combinations thereof. In some embodiments, the radiation is delivered to the animal using a linear accelerator. In still other embodiments, the radiation is delivered using a gamma knife.

The source of radiation can be external or internal to the animal. External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. While the beam of radiation is localized to the tumor site, it is nearly impossible to avoid exposure of normal, healthy tissue. However, external radiation is usually well tolerated by animals. Internal radiation therapy involves implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site including the use of delivery systems that specifically target cancer cells (*e.g.*, using particles attached to cancer cell binding ligands). Such implants can be removed following treatment, or left in the body inactive. Types of internal radiation therapy include, but are not limited to, brachytherapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.

The animal may optionally receive radiosensitizers (*e.g.*, metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4-nitroimidazoles, 2H-isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-1H-imidazole-1-ethanol, nitroaniline derivatives, DNA-affinic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotetrazole derivative, 3-nitro-1,2,4-triazole, 4,5-dinitroimidazole derivative, hydroxylated texaphrins, cisplatin, mitomycin, tiripazamine, nitrosourea, mercaptopurine, methotrexate, fluorouracil, bleomycin, vincristine, carboplatin, epirubicin, doxorubicin, cyclophosphamide, vindesine, etoposide, paclitaxel, heat (hyperthermia), and the like), radioprotectors (*e.g.*, cysteamine, aminoalkyl dihydrogen phosphorothioates, amifostine (WR 2721), IL-1, IL-6, and the like). Radiosensitizers enhance the killing of tumor cells. Radioprotectors protect healthy tissue from the harmful effects of radiation.

Any type of radiation can be administered to an animal, so long as the dose of radiation is tolerated by the animal without unacceptable negative side-effects. Suitable types of radiotherapy include, for example, ionizing (electromagnetic) radiotherapy (*e.g.*, X-rays or gamma rays) or particle beam radiation therapy (*e.g.*, high linear energy radiation). Ionizing radiation is defined as radiation comprising particles or photons that have sufficient energy to produce ionization, *i.e.*, gain or loss of electrons (as described in, for example, U.S. 5,770,581 incorporated herein by reference in its entirety). The effects of radiation can be at least partially controlled by the clinician. In one embodiment, the dose of radiation is fractionated for maximal target cell exposure and reduced toxicity.

In one embodiment, the total dose of radiation administered to an animal is about .01 Gray (Gy) to about 100 Gy. In another embodiment, about 10 Gy to about 65 Gy (*e.g.*, about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, or 60 Gy) are administered over the course of treatment. While in some embodiments a complete dose of radiation can be administered over the course of one day, the total dose is ideally fractionated and administered over several days. Desirably, radiotherapy is administered over the course of at least about 3 days, *e.g.*, at least 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1-8 weeks). Accordingly, a daily dose of radiation will comprise approximately 1-5 Gy (*e.g.*, about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy, 4 Gy, 4.2 Gy, or 4.5 Gy), or 1-2 Gy (*e.g.*, 1.5-2 Gy). The daily dose of radiation should be sufficient to induce destruction of the targeted cells. If stretched over a period, in one embodiment, radiation is not administered every day, thereby allowing the animal to rest and the effects of the therapy to be realized. For example, radiation desirably is administered on 5 consecutive days, and not administered on 2 days, for each week of treatment, thereby allowing 2 days of rest per week. However, radiation can be administered 1 day/week, 2 days/week, 3 days/week, 4 days/week, 5 days/week, 6 days/week, or all 7 days/week, depending on the animal's responsiveness and any potential side effects. Radiation therapy can be initiated at any time in the therapeutic period. In one embodiment, radiation is initiated in week 1 or week 2, and is administered for the remaining duration of the therapeutic period. For example, radiation is administered in weeks 1-6 or in weeks 2-6 of a therapeutic period comprising 6 weeks for treating, for instance, a solid tumor. Alternatively, radiation is administered in weeks 1-5 or weeks 2-5 of a therapeutic period comprising 5 weeks. These exemplary radiotherapy administration schedules are not intended, however, to limit the present invention.

Antimicrobial therapeutic agents may also be used as therapeutic agents in the present invention. Any agent that can kill, inhibit, or otherwise attenuate the function of microbial organisms may be used, as well as any agent contemplated to have such activities.

Antimicrobial agents include, but are not limited to, natural and synthetic antibiotics, antibodies, inhibitory proteins (*e.g.*, defensins), antisense nucleic acids, membrane disruptive agents and the like, used alone or in combination. Indeed, any type of antibiotic may be used including, but not limited to, antibacterial agents, antiviral agents, antifungal agents, and the like.

In some embodiments of the present invention, a compound of the invention and one or more therapeutic agents or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different concentrations, by different administration routes, *etc.* In some embodiments, the compound is administered prior to the therapeutic or anticancer agent, *e.g.*, 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks prior to the administration of the therapeutic or anticancer agent. In some embodiments, the compound is administered after the therapeutic or anticancer agent, *e.g.*, 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, or 1, 2, 3, or 4 weeks after the administration of the anticancer agent. In some embodiments, the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, *e.g.*, the compound is administered daily while the therapeutic or anticancer agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.

Compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, the compounds may be administered to mammals, *e.g.* humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis. In one embodiment, about 0.01 to about 25 mg/kg is orally administered to treat, ameliorate, or prevent such disorders. For intramuscular injection, the dose is generally about one-half of the

oral dose. For example, a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, or from about 0.01 to about 5 mg/kg.

The unit oral dose may comprise from about 0.01 to about 1000 mg, for example, about 0.1 to about 100 mg of the compound. The unit dose may be administered one or more
5 times daily as one or more tablets or capsules each containing from about 0.1 to about 10 mg, conveniently about 0.25 to 50 mg of the compound or its solvates.

In a topical formulation, the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier. In a one embodiment, the compound is present at a concentration of about 0.07-1.0 mg/ml, for example, about 0.1-0.5 mg/ml, and in one
10 embodiment, about 0.4 mg/ml.

In addition to administering the compound as a raw chemical, the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically. The
15 preparations, particularly those preparations which can be administered orally or topically and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion,
20 injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound(s), together with the excipient.

The pharmaceutical compositions of the invention may be administered to any patient which may experience the beneficial effects of the compounds of the invention. Foremost among such patients are mammals, *e.g.*, humans, although the invention is not intended to be
25 so limited. Other patients include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like).

The compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal,
30 intracranial, intranasal or topical routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.

Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a

suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin

5 hydrocarbons.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.

15 The topical compositions of this invention are formulated in one embodiment as oils, creams, lotions, ointments and the like by choice of appropriate carriers. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C₁₂). The carriers may be those in which the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Additionally, transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762; each herein incorporated by reference in its entirety.

Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight. Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.

30 One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the compositions and methods described above can

readily be achieved using expertise available in the art and are within the scope of the invention.

EXAMPLES

The following examples are illustrative, but not limiting, of the compounds, compositions, and methods of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

10


Example I.

This example describes various synthetic methods for obtaining the compounds of the present invention.

A method of preparing bicyclic quinone derivatives of formula I is shown in the scheme 1, and scheme 2.

15

Scheme 1^a Synthesis of compounds I-a.



^a Reagents and conditions: (a) NaClO₃, con. HCl, room temperature-50 °C, 2 h; (b) Arylamine, CeCl₃·7H₂O, EtOH, 60-90 °C, 2-6 h;

20

wherein R¹, R², R^{3a}, R^{3b}, R^{3c}, and R^{3d} are the same as defined above.


The detailed synthetic methods in scheme 1 are described below.

The preparation of the compound of formula I-a is as follow (Scheme 1): Chloroxidation of 8-hydroxyquinoline derivatives 1-1 with sodium chlorate in the presence of concentrated hydrochloric acid under simple magnetic stirring afforded the 6,7-dichloro-5,8-quinolinediones 1-2. The compound of formula I is prepared by condensation reaction of 6,7-dichloro-5,8-quinolinediones 1-2 and arylamines. A solvent used in this reaction is C₁-C₃ lower alcohol such as methanol, ethanol and isopropanol. Additive used in this regioselective condensation of appropriate aminobenzenes to 6 position of 6,7-dichloroquinoline-5,8-diones 1-2 in the presence of Lewis acid such as cerium(III) chloride heptahydrate (CeCl₃·7H₂O),

30

nickel(II) chloride hexahydrate ($\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$), and iron(III) chloride hexahydrate $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$. The reaction is carried at reflux temperature for 2-6 hours.

Scheme 2^a Synthesis of compounds I-b.



5 ^a Reagents and conditions: (c) KOH, MeOH, H_2O , 80-100 °C, 2-5 hours.

wherein R^1 , and R^2 are the same as defined above.


The detailed synthetic methods in scheme 2 are described below.

The compound of formula **I-b** is prepared by reacting compound **I-a'** dissolved in methanol and water with potassium hydroxide at 80 °C for 2 hours (Scheme 2).

10 A method of preparing bicyclic quinone derivatives of formula II is shown in the scheme

3. The detailed synthetic methods are described below.

15 **Scheme 3^a Synthesis of compounds II.**



^a Reagents and conditions: (a) Meldrum's acid, methylorthoformate, reflux, 7 h; (b) $\text{HNO}_3/\text{SiO}_2$, CH_2Cl_2 , rt; (c) PhOPh , 250 °C, 15 min; (d) POBr_3 , DMF, 0 °C - rt; (e) Substituted boronic acid, $\text{Pd}(\text{PPh}_3)_4$, K_2CO_3 , dioxane, H_2O , reflux, 6 h; (f) Fe , AcOH , MeOH , H_2O , reflux, 30 min; (g) acyl chloride, TEA, THF, 0 °C - rt, overnight; (h) $(\text{NH}_4)_2\text{Ce}(\text{NO}_3)_6$, CH_3CN , H_2O , 0 °C - rt, 2 h; (i) amine, dry chloroform, rt, 0.5 – 8 h; (j) Amine, CHCl_3 , reflux, 4 h.

wherein R^1 , R^4 , and X are the same as defined above.


The detailed synthetic methods in scheme 3 are described below.

- 10 The preparation of the compound of formula II-a and formula II-b are depicted as follow:
The synthesis of I-c is depicted in Scheme 3. Nitroquinolone 1-7 were synthesized by the established method (Heterocycl. Commun. 2000, 6, 539-544; Synth. Commun. 1985, 15, 125-133). The solution of Meldrum's acid was heated in methylorthoformate under reflux for

2 h, followed by the addition of arylamine **1-4**. The mixture was heated under reflux for an additional 5 h. Subsequent regioselective nitration of compound **1-5** with nitric acid supported on silica gel in dichloromethane afforded **1-6**. Cyclization of **1-6** to the corresponding nitroquinolone **1-7** was accomplished by boiling in diphenyl ether at 250 °C for 15 min. Treatment of quinolone **1-7** with POBr₃ in DMF gave the 4-bromoquinoline **1-8**. Intermediate **1-8** underwent the Heck coupling reaction with the respective substituted boronic acids in dioxane using Pd(PPh₃)₄ as a catalyst to produce **1-9**. Subsequent reduction of the nitro group with activated iron provided aniline product **1-10**, which was then reacted with appropriate acyl chloride in the presence of trimethylamine to afford **1-11**. The final oxidation of **1-11** with ceric ammonium nitrate in acetonitrile and H₂O gave the desired compounds **1-12**. The compounds of formula **II-a** were prepared by reacting compound **1-12** with the appropriate amines in anhydrous chloroform at from 0 °C to room temperature for 3-8 hours. Chloroform as a solvent can be replaced to dichloromethane, *N,N*- dimethylformamide, or methanol. The compounds of formula **II-b** were prepared by reacting compound **1-12** with the appropriate amines in anhydrous chloroform by heating for 3-8 hours. Chloroform as a solvent can be replaced to dichloromethane, *N,N*- dimethylformamide, or methanol.

A method of preparing tetracyclic quinone derivatives of formula III is shown in scheme 4. The detailed synthetic methods are described below.

20 Scheme 4^a Synthesis of compounds III.



^a Reagents and conditions. (a) NaClO₃, con. HCl, room temperature-50 °C, 2 h; (b) Arylamine, CeCl₃·7H₂O, EtOH, 60-80 °C, 2-5 h; (c) NaN₃, H₂O, DMF, 80-95 °C, 2-8 h.

wherein R¹, R², R^{3a}, R^{3b}, R^{3c}, and R^{3d} are the same as defined above.

The detailed synthesis of compounds in scheme 4 is described hereunder.

The preparation of the compound of formula **III** is as follow: Chloroxidation of 8-hydroxyquinoline derivatives **2-1** with sodium chlorate in the presence of concentrated hydrochloric acid under simple magnetic stirring afforded the 6,7-dichloro-5,8-quinolinediones **2-2**. Condensation reaction of 6,7-dichloro-5,8-quinolinediones **I** with
5 arylamines in the presence of Lewis acid, such as cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$), nickel(II) chloride hexahydrate ($\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$), or iron(III) chloride hexahydrate $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$. The solvent used in this reaction is $\text{C}_1\text{-C}_3$ lower alcohol such as methanol, ethanol and isopropanol at 60- 90 °C for 2-6 hours. After the reaction is completed, the solvent was removed under reduced pressure. Then the sodium azide, DMF and a drop of
10 water were added. The mixture was stirred at 65-90 °C for 2-6 hours to obtain the compounds of formula **III**.

General Experimental Methods

General Methods. Reagents and anhydrous solvents were used without further
15 purification and purchased from commercial sources. Reaction progress was monitored by UV absorbance using thin-layer chromatography (TLC) on aluminum-backed precoated silica plates from Silicycle (SiliaPlate, 200 μm thickness, F254). Purifications using flash chromatography were performed using Silicycle silica gel (SiliaFlash F60, 40–63 μm , 230–400 mesh, PN R10030B), and a small percentage of compounds were purified using a
20 Biotage Isolera chromatography system equipped with 10 and 25 g Ultra-SNAP Cartridge columns (25 μm spherical silica). ^1H NMR spectra were obtained using a Varian (300 or 400 MHz) instrument. Spectral data are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, and coupling constants are reported in Hz, followed by integration. A Shimadzu LCMS 20-20 system was
25 utilized for generating HPLC traces, obtaining mass spectrometry data, and evaluating purity. The system is equipped with a PDA UV detector and Kinetex 2.6 μm , XB-C18 100 Å, 75 mm $\times$ 4.6 mm column, which was used at room temperature. HPLC gradient method utilized a 1% to 90% MeCN in H_2O with 0.01% formic acid over 20 min with a 0.50 mL/min flow rate. Purity of final compounds ($\geq 95\%$) was assessed at 254 nm using the described column and method. Reverse-phase preparatory purifications were performed on a Shimadzu LC-20
30 modular HPLC system. This system utilized a PDA detector and a Kinetex 5 μm XB-C18 100 Å, 150 mm $\times$ 21.2 mm column. Purification methods used a 27 min gradient from 10% to 90% MeCN in H_2O with 0.02% trifluoroacetic acid.

General Protocol A: Chloroxidation. Sodium chlorate (5.3 g, 50 mmol) was added over a period of 1 h to a stirred solution of 8-hydroxyquinoline derivatives (10 mmol) in concentrated HCl (100 mL) at 50 °C. The reaction mixture then was allowed to stir for 2 h and there after diluted to 200 mL with distilled water. The yellow precipitate that formed was removed by filtration and discarded. The filtrate was extracted with CH₂Cl₂ (3 × 50 mL), and the organic phases were combined, washed with water and brine, dried (Na₂SO₄), and concentrated in vacuo. The solid was recrystallized in MeOH to afford pure bright yellow crystals of 6,7-dichloro-5,8-quinolinediones **1-2** and **2-2**.

General Protocol B: Regioselective condensation. A solution of 6,7-dichloro-5,8-quinolinediones **1-2** or **2-2** (1.0 equiv.), cerium (III) chloride heptahydrate (CeCl₃·7 H₂O, 1.1 equiv) and appropriate arylamines (1.0 equiv) in ethanol was stirred at 60-90 °C for 2–6 h. After completion of reaction by TLC, it was cooled, filtered, and recrystallized with ethanol to give dark purple powder of the desire compounds **I-a**.

General Protocol C: Hydrolysis reaction. 7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-diones **1-a'** (0.66 mmol) was added to a stirred solution of KOH (0.37 g, 6.6 mmol) in MeOH: H₂O (3:1) and heated to 80 °C. After 2 h, the dark red solution was cooled to rt. 10 mL of ethyl acetate was added, which was washed with water (10 mL) and saturated aqueous NaCl solution (10 mL). The organic layer was dried over sodium sulfate, and subsequently the solvent was distilled off under reduced pressure. This was purified by silica gel column chromatography, the desired compound **28 (1-b)** was obtained.

General Protocol D: Bromination reaction. To a suspension of nitroquioline **1-7** (84 mg, 0.034 mmol) in DMF, POBr₃ was added dropwise at 0°C. The suspension became clear and then cloudy during this process. After 1h, the reaction mixture was diluted with 28% ammonia solution and extracted with ethyl acetate. The combined extracts were washed with brine, dried over anhydrous Na₂SO₄ and removed in vacuo. The residue was purified on flash column chromatography with ethyl acetate and hexane as elution to give compound 4-bromo-5,8-dimethoxy-6-nitroquinoline **1-8** as a yellow solid.

General Protocol E: Coupling reaction. Compound **1-8** (10 mg, 0.068 mmol), boronic acids (0.068 mmol) and K₂CO₃ (11 mg, 0.081 mmol) were introduced in a 25 mL round-bottom flask degassed with nitrogen gas. The mixture of 1,4 dioxane and water (5 mL, 4:1) were added and then stirred for 5 min, followed by the addition of Pd(PPh₃)₄ (4 mg, 0.003 mmol). The mixture was refluxed for 6 h under a nitrogen atmosphere. The organic phase was

evaporated and resulting oil was purified by column chromatography to give coupling products **1-9**.

General Protocol F: Reductive acylation. To a refluxing solution of methanol (8 mL), glacial acetic acid (1 mL) and water (1 mL) were added in succession compound **1-9** (0.56 mmol) and iron powder (158 mg, 2.82 mmol). The mixture was refluxed for another 30 min with vigorous stirring. The reaction solution was filtered through celite. The organic phase of the filtrate was removed in vacuo and the residue was added saturated aqueous K_2CO_3 solution (20 mL). The resulting mixture was extracted with ethyl acetate, and the organic phase was washed with H_2O , dried over Na_2SO_4 , and concentrated to provide the crude amino product amines **1-10** which used directly for next step of reaction. All the solid products obtained were dissolved in anhydrous THF solution, followed by trimethylamine (571 mg, 5.64 mmol). The mixture was cooled to $0^\circ C$ and acyl chlorides (2.82 mmol) was added dropwise. After 1 h of stirring at $0^\circ C$, the temperature was raised to room temperature and the stirring was continued for overnight. After removal of the solvent in vacuo, the residue was purified by column chromatography to give amides **1-11** (152 mg, 66%).

General Protocol G: Oxidation reaction. To a stirred solution of **1-11** (0.028 mmol) in a mixture of $CH_3CN:H_2O$ (1 mL, 11) was added a solution of ceric ammonium nitrate (31 mg, 0.056 mmol) in $CH_3CN:H_2O$ (1 mL, 2:1) dropwise at $0^\circ C$. The reaction mixture was stirred at room temperature for 30 min before being diluted with an ice-water slurry (5 mL) and taken up by dichloromethane. The organic layer was combined, dried, concentrated and purified by column chromatography to give oxidation products **1-12**.

General Protocol H: Substitution reaction. To a solution of the **1-12** (0.05 mmol) dissolved in dry chloroform (2 mL), amines (2.0 mmol) was added and the resulting red-brown solution was stirred at from $0^\circ C$ to room temperature until complete disappearance of the starting material (TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure products **1-c**.

General Protocol I: Double substitution reaction. To a solution of the **1-12** (0.05 mmol) dissolved in dry chloroform (2 mL), amines (2.0 mmol, 200.3 mg) was added and the resulting red-brown solution was stirred at reflux until complete disappearance of the starting material (TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure products (**1-d**).

General Protocol J: A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($CeCl_3 \cdot 7 H_2O$, 0.11 equiv.) and appropriate arylamines (0.1 equiv) in

ethanol (2 mL) was stirred at 60-90 °C for 2–6 h. Next, most of the ethanol was removed under vacuum to afford crude product 6-arylamino-7-chloro-5,8-quinolinediones **I**. DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 65-90 °C for 2-6 h. The reaction mixture was
5 chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography to afford compounds **II**.

General Protocol N: Cytotoxicity.

MTT assay

The evaluation of cytotoxicity was based on the reduction of MTT dye by viable cells to
10 give purple formazan products, which can be measured spectrophotometrically at 540 nm. One hundred eighty microliters of cancer cells were seeded into 96-well plates at 3,500-4,000 cells/well and incubated at 37°C overnight before the indicated treatments. After 72h, 20 µl of MTT solution (3 mg/ml) was added and incubated again for 3 h. After removal of media and solubilization of formazan crystals in 150 µL of DMSO, the absorbance was measured at
15 570 nm. Percentage of cell growth inhibition was expressed as $1 - [(A-B)/(C-B)] \times 100\%$ (A, B and C were the absorbance values from experimental, blank and control cells, respectively).

Representative compounds were tested in 60 cell lines (NCI60) at the National Cancer Institute, Developmental Therapeutics Program.

20 Example II.

¹HNMR data, LC/MS data and purity of the compounds of formula I, formula II, and formula III prepared by the above procedure are summarized as follow:

Example 1: 7-Chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione (1). Following general protocol B. A solution of 2,6-difluoro-4-(4-methylpiperazin-
25 1-yl)aniline (22.7 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (28.8 mg, 69% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 9.01 (s, 1H), 8.55 (d, *J* = 7.7 Hz, 1H), 7.89 (s, 1H), 6.75 (d, *J* = 10.8 Hz, 2H),
30 3.97 (s, 2H), 3.64 (s, 2H), 3.35 (d, *J* = 11.5 Hz, 4H), 3.00 (s, 3H). LCMS (ESI) 419.00 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 2: 7-Chloro-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione (2). Following general protocol B. A solution of 4-(4-(methylsulfonyl)piperazin-1-

yl)aniline (25.5 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (31.2 mg, 70% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.91 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.47 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.76 (dd, *J* = 7.9, 4.8 Hz, 1H), 7.09 (d, *J* = 9.0 Hz, 2H), 6.98 (d, *J* = 9.0 Hz, 2H), 3.39 – 3.32 (m, 8H), 2.87 (s, 3H). LCMS (ESI) 447.00 [M + H]⁺. HPLC purity at 254 nm, 95.6%.

Example 3: 7-Chloro-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione (3). Following general protocol B. A solution of 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (18.5 mg, 41% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.96 (d, *J* = 5.1 Hz, 1H), 8.53 (d, *J* = 6.4 Hz, 1H), 7.87 – 7.77 (m, 1H), 7.59 – 7.47 (m, 2H), 7.42 (dd, *J* = 8.6, 2.3 Hz, 1H), 3.62 (d, *J* = 9.9 Hz, 2H), 3.28 – 3.20 (m, 6H), 3.01 (s, 3H). LCMS (ESI) 451.10 [M + H]⁺. HPLC purity at 254 nm, 98.3%.

Example 4: 5-((7-Chloro-5,8-dioxo-5,8-dihydroquinolin-6-yl)amino)-2-(4-methylpiperazin-1-yl) benzonitrile (4). Following general protocol B. A solution of 5-amino-2-(4-methylpiperazin-1-yl)benzonitrile (21.6 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 5-((7-chloro-5,8-dioxo-5,8-dihydroquinolin-6-yl)amino)-2-(4-methylpiperazin-1-yl) benzonitrile was recovered as a dark purple solid (22.0 mg, 54% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.97 (d, *J* = 4.4 Hz, 1H), 8.52 (d, *J* = 7.8 Hz, 1H), 7.82 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.53 (d, *J* = 2.3 Hz, 1H), 7.44 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.27 (d, *J* = 8.8 Hz, 1H), 3.72 (t, *J* = 12.5 Hz, 4H), 3.41 (t, *J* = 11.5 Hz, 2H), 3.24 (d, *J* = 11.0 Hz, 2H), 3.04 (s, 3H). LCMS (ESI) 408.10 [M + H]⁺. HPLC purity at 254 nm, 99.2%.

Example 5: 7-Chloro-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione (5). Following general protocol B. A solution of 4-(4-methylpiperazin-1-yl)aniline (19.1 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (27.1 mg, 71% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.92 (s, 1H), 8.51

(dd, $J = 7.9, 1.1$ Hz, 1H), 7.79 (dd, $J = 7.8, 4.8$ Hz, 1H), 7.21 – 7.12 (m, 2H), 7.09 – 6.99 (m, 2H), 3.90 (d, $J = 13.1$ Hz, 2H), 3.70 – 3.60 (m, 2H), 3.36 – 3.26 (m, 2H), 3.09 (t, $J = 12.1$ Hz, 2H), 3.01 (s, 3H). LCMS (ESI) 383.1 $[M + H]^+$. HPLC purity at 254 nm, 98.8%.

Example 6: 7-Chloro-6-((4-(piperidin-1-yl)phenyl)amino)quinoline-5,8-dione (6).

5 Following general protocol B. A solution of 4-(piperidin-1-yl)aniline (17.6 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(piperidin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (22.4 mg, 61% yield). ^1H NMR (300 MHz, Methanol- d_4) δ 8.97 (d, $J = 4.4$ Hz, 1H), 8.53 (d, $J = 7.6$ Hz, 1H),
10 7.83 (dd, $J = 7.2, 4.6$ Hz, 1H), 7.63 (d, $J = 8.1$ Hz, 2H), 7.34 (d, $J = 8.6$ Hz, 2H), 3.71 – 3.61 (m, 4H), 2.13 – 1.99 (m, 4H), 1.89 – 1.72 (m, 2H). LCMS (ESI) 368.00 $[M + H]^+$. HPLC purity at 254 nm, 98.9%.

Example 7: 6-((4-(1H-Imidazol-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione (7).

Following general protocol B. A solution of 4-(1H-imidazol-1-yl)aniline (15.9 mg, 0.1
15 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 6-((4-(1H-imidazol-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione was recovered as a dark purple solid (19.2 mg, 55% yield). ^1H NMR (300 MHz, Methanol- d_4) δ 9.43 (s, 1H), 8.98 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.55 (dd, $J = 7.9, 1.7$ Hz, 1H), 8.09 (t, $J = 1.7$ Hz, 1H), 7.84 (dd, $J = 7.9, 4.8$
20 Hz, 1H), 7.79 – 7.76 (m, 1H), 7.73 (d, $J = 8.9$ Hz, 2H), 7.41 (d, $J = 8.9$ Hz, 2H). LCMS (ESI) 351.00 $[M + H]^+$. HPLC purity at 254 nm, 96.3%.

Example 8: 7-Chloro-6-((4-(pyridin-4-yl)phenyl)amino)quinoline-5,8-dione (8). Following general protocol B. A solution of 4-(pyridin-4-yl)aniline (17.0 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41
25 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(pyridin-4-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (17.7 mg, 49% yield). ^1H NMR (300 MHz, Methanol- d_4) δ 8.99 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.82 (d, $J = 7.0$ Hz, 2H), 8.56 (dd, $J = 7.9, 1.7$ Hz, 1H), 8.40 (d, $J = 7.0$ Hz, 2H), 8.07 – 8.00 (m, 2H), 7.85 (dd, $J = 7.9, 4.8$ Hz, 1H), 7.37 (d, $J = 8.8$ Hz, 2H). LCMS (ESI) 361.90 $[M + H]^+$. HPLC
30 purity at 254 nm, 96.0%.

Example 9: 7-Chloro-6-((4-(thiazol-2-yl)phenyl)amino)quinoline-5,8-dione (9). Following

general protocol B. A solution of 4-(thiazol-2-yl)aniline (17.6 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41

mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(thiazol-2-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (18.0 mg, 49% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.98 (d, *J* = 4.8 Hz, 1H), 8.55 (d, *J* = 8.7 Hz, 1H), 7.96 (d, *J* = 8.4 Hz, 2H), 7.89 (d, *J* = 3.7 Hz, 1H), 7.84 (dd, *J* = 8.5, 4.2 Hz, 1H), 7.63 (d, *J* = 2.9 Hz, 1H), 7.27 (d, *J* = 8.6 Hz, 2H). LCMS (ESI) 368.00 [M + H]⁺. HPLC purity at 254 nm, 97.9%.

Example 10: 6-((4-(4-Acetylpiperazin-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione (10). Following general protocol B. A solution of 1-(4-(4-aminophenyl)piperazin-1-yl)ethan-1-one (21.9 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 6-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-7-chloroquinoline-5,8-dione was recovered as a dark purple solid (25.4 mg, 62% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.95 (s, 1H), 8.52 (d, *J* = 7.6 Hz, 1H), 7.85 – 7.76 (m, 1H), 7.15 (d, *J* = 8.9 Hz, 2H), 7.08 (d, *J* = 8.9 Hz, 2H), 3.84 – 3.71 (m, 4H), 3.29 – 3.23 (m, 4H), 2.18 (s, 3H). LCMS (ESI) 411.10 [M + H]⁺. HPLC purity at 254 nm, 99.4%.

Example 11: 7-Chloro-6-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)quinoline-5,8-dione (11). Following general protocol B. A solution of tert-butyl 4-(4-amino-2-fluorophenyl)piperazine-1-carboxylate (29.5 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (23.5 mg, 61% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.96 (d, *J* = 4.8 Hz, 1H), 8.52 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.81 (dd, *J* = 7.8, 4.7 Hz, 1H), 7.10 (t, *J* = 9.1 Hz, 1H), 7.05 – 6.94 (m, 2H), 3.46 – 3.40 (m, 4H), 3.38 – 3.34 (m, 4H). LCMS (ESI) 378.00 [M + H]⁺. HPLC purity at 254 nm, 99.5%.

Example 12: 7-Chloro-6-((4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione (12). Following general protocol B. A solution of 4-(4-(4-methoxyphenyl)piperazin-1-yl)aniline (28.3 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (28.4 mg, 60% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.96 (d, *J* = 5.5 Hz, 1H), 8.52 (d, *J* = 7.4 Hz, 1H), 7.85 – 7.77 (m, 1H), 7.55 (d, *J* = 8.6 Hz, 2H), 7.14 (t, *J* = 10.1 Hz, 6H), 3.87 (s, 3H), 3.80 –

3.74 (m, 4H), 3.67 – 3.60 (m, 4H). LCMS (ESI) 475.10 [M + H]⁺. HPLC purity at 254 nm, 98.9%.

Example 13: 7-Chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione (13). Following general protocol B. A solution of 4-(4-methylpiperazin-1-yl)aniline (19.1 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (24.1 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (23.4 mg, 59% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.37 (d, *J* = 8.0 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.17 – 7.12 (m, 2H), 7.04 (d, *J* = 9.1 Hz, 2H), 4.97 (s, 2H), 3.88 (s, 2H), 3.59 (d, *J* = 20.2 Hz, 2H), 3.08 (s, 2H), 3.00 (s, 3H), 2.72 (s, 3H). LCMS (ESI) 397.00 [M + H]⁺. HPLC purity at 254 nm, 99.3%.

Example 14: 7-Chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methylquinoline-5,8-dione (14). Following general protocol B. A solution of 2,6-difluoro-4-(4-methylpiperazin-1-yl)aniline (22.7 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (24.1 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methylquinoline-5,8-dione was recovered as a dark purple solid (30.2 mg, 70% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.36 (d, *J* = 8.1 Hz, 1H), 7.66 (d, *J* = 8.2 Hz, 1H), 6.76 (d, *J* = 10.2 Hz, 2H), 3.96 (s, 2H), 3.60 (s, 2H), 3.18 (dd, *J* = 35.3, 14.7 Hz, 4H), 3.00 (s, 3H), 2.72 (s, 3H). LCMS (ESI) 433.20 [M + H]⁺. HPLC purity at 254 nm, 99.4%.

Example 15: 7-Chloro-2-methyl-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione (15). Following general protocol B. A solution of 4-(4-(methylsulfonyl)piperazin-1-yl)aniline (25.5 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (24.1 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-2-methyl-6-((4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (35.4 mg, 77% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.37 (d, *J* = 7.5 Hz, 1H), 7.65 (d, *J* = 8.7 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 2H), 7.02 (d, *J* = 8.8 Hz, 2H), 3.40 (d, *J* = 8.8 Hz, 8H), 2.91 (s, 3H), 2.72 (s, 3H). LCMS (ESI) 461.10 [M + H]⁺. HPLC purity at 254 nm, 98.8%.

Example 16: 5-(7-Chloro-2-methyl-5,8-dioxo-5,8-dihydroquinolin-6-yl)-2-(4-methylpiperazin-1-yl) benzonitrile (16). Following general protocol B. A solution of 5-

amino-2-(4-methylpiperazin-1-yl)benzonitrile (21.6 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (21.6 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 5-((7-chloro-2-methyl-5,8-dioxo-5,8-dihydroquinolin-6-yl)amino)-2-(4-methylpiperazin-1-yl)benzonitrile was recovered as a dark purple solid (28.6 mg, 68% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.35 (d, *J* = 7.7 Hz, 1H), 7.65 (d, *J* = 7.6 Hz, 1H), 7.50 (s, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 7.24 (d, *J* = 8.8 Hz, 1H), 3.70 (t, *J* = 14.1 Hz, 6H), 3.45 – 3.36 (m, 2H), 3.01 (s, 3H), 2.71 (s, 3H). LCMS (ESI) 422.10 [M + H]⁺. HPLC purity at 254 nm, 99.2%.

Example 17: 7-Chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)

amino)quinoline-5,8-dione (17). Following general protocol B. A solution of 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (24.1 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-2-methyl-6-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione was recovered as a dark purple solid (31.0 mg, 67% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.38 (d, *J* = 8.3 Hz, 1H), 7.68 (d, *J* = 8.3 Hz, 1H), 7.56 (d, *J* = 8.9 Hz, 1H), 7.51 (s, 1H), 7.41 (d, *J* = 6.8 Hz, 1H), 3.62 (d, *J* = 10.7 Hz, 2H), 3.25 (s, 6H), 3.01 (s, 3H), 2.73 (s, 3H). LCMS (ESI) 456.20 [M + H]⁺. HPLC purity at 254 nm, 97.9%.

Example 18: 7-Chloro-6-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-2-methylquinoline-5,8-

dione (18). Following general protocol B. A solution of 2-methoxy-4-(4-methylpiperazin-1-yl)aniline (22.1 mg, 0.1 mmol), 6,7-dichloro-2-methylquinoline-5,8-dione (24.1 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-methylquinoline-5,8-dione was recovered as a dark purple solid (32.0 mg, 75% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.31 (d, *J* = 7.8 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.08 (d, *J* = 8.0 Hz, 1H), 6.65 (s, 1H), 6.59 (d, *J* = 9.2 Hz, 1H), 3.90 (s, 2H), 3.79 (s, 3H), 3.62 (s, 2H), 3.28 – 3.21 (m, 2H), 3.12 (d, *J* = 12.4 Hz, 2H), 2.99 (s, 3H), 2.70 (s, 3H). LCMS (ESI) 427.10 [M + H]⁺. HPLC purity at 254 nm, 98.8%.

Example 19: 7-Chloro-6-[3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl]quinoline-5,8-

dione (19). Following general protocol B. A solution of 3,5-difluoro-4-(4-methylpiperazin-1-yl)aniline (22.7 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-

dione was recovered as a dark purple solid (33.0 mg, 79% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.78 (brs, 1H), 9.39 (s, 1H), 9.00 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.39 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.81 (dd, *J* = 7.9, 4.7 Hz, 1H), 6.88 (d, *J* = 11.0 Hz, 2H), 3.37 – 3.10 (m, 8H), 2.87 (s, 3H). LCMS (ESI) 419.00 [M + H]⁺. HPLC purity at 254 nm, 98.2%.

- 5 **Example 22: 7-Chloro-6-[4-(ethylamino)-2-(trifluoromethyl)phenyl]quinoline-5,8-dione (22).** Following general protocol B. A solution of N¹-ethyl-3-(trifluoromethyl)benzene-1,4-diamine (20.4 mg, 0.1 mmol), 6,7-dichloroquinoline-5,8-dione (22.7 mg, 0.1 mmol), and Cerium(III) chloride heptahydrate (41 mg, 0.11 mmol) in ethanol (2 mL) was stirred at 65 °C for 3 h. 7-chloro-6-((4-(ethylamino)-2-(trifluoromethyl)phenyl)amino)quinoline-5,8-dione
10 was recovered as a dark purple solid (17.8 mg, 45% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.93 (s, 1H), 8.45 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.81 (dd, *J* = 7.9, 4.6 Hz, 1H), 7.16 – 7.07 (m, 2H), 6.89 (dt, *J* = 8.7, 0.7 Hz, 1H), 4.05 – 3.94 (m, 2H), 1.34 – 1.29 (m, 3H). LCMS (ESI) 396.00 [M + H]⁺. HPLC purity at 254 nm, 97.4%.

- Example 28: 7-Chloro-6-[2-fluoro-6-hydroxy-4-(4-methylpiperazin-1-yl)phenyl]quinoline-5,8-dione (28).** Following general protocol C. 7-chloro-6-((2,6-difluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)quinoline-5,8-dione **1** (0.66 mmol) was added to a stirring solution of KOH (0.37 g, 6.6 mmol) in MeOH: H₂O (3:1) and heated to 80 °C. After 2 h, the dark red solution was cooled to rt. 10 mL of ethyl acetate was added, which was washed with water (10 mL) and saturated aqueous NaCl solution (10 mL). The organic layer was dried over sodium sulfate, and subsequently
20 the solvent was distilled off under reduced pressure. This was purified by silica gel column chromatography, the desired compound **28** was obtained (71%). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.73 (s, 1H), 8.46 (t, *J* = 8.2 Hz, 1H), 7.73 (s, 1H), 6.77 – 6.51 (m, 2H), 3.86 (s, 2H), 3.62 (s, 2H), 3.37 – 3.32 (m, 2H), 3.07 (s, 2H), 3.00 (s, 3H). LCMS (ESI) 417.00 [M + H]⁺. HPLC purity at 254 nm, 100%.

- 25 **Example 31: (E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide (31).** Following general protocol H. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (2 mL), pyrrolidine (2.0 mmol, 142 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (0.5 h, TLC analysis). The resulting solution
30 was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide as a dark red solid (13.8 mg, 0.03 mmol, 59%), (HPLC purity at 254nm, 98.2%). ¹H NMR (300 MHz, CDCl₃-*d*) δ 8.78 (d, *J* = 4.8 Hz, 1H), 8.45 (d, *J*

= 16.4 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.64 – 7.59 (m, 2H), 7.49 (s, 1H), 7.22 – 7.09 (m, 3H), 3.77 – 3.58 (m, 6H), 2.74 – 2.66 (m, 2H), 2.25 – 2.14 (m, 2H), 2.01 – 1.91 (m, 4H). LCMS (ESI) 468.14 $[M + H]^+$.

Example 32: (E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide (32). Following general protocol H. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (2 mL), piperidine (2.0 mmol, 170 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (1 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide as a dark red solid (18.0 mg, 0.04 mmol, 75%), (HPLC purity at 254nm, 97.0%). ^1H NMR (300 MHz, CDCl_3 -d) δ 8.88 (d, J = 4.8 Hz, 1H), 8.39 (d, J = 17.0 Hz, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.66 – 7.59 (m, 3H), 7.49 (s, 1H), 7.22 – 7.10 (m, 3H), 3.69 (t, J = 6.2 Hz, 3H), 3.48 – 3.40 (m, 4H), 2.72 (t, J = 6.2 Hz, 2H), 2.21 (t, J = 6.0 Hz, 3H), 1.80 – 1.66 (m, 6H). LCMS (ESI) 482.16 $[M + H]^+$.

Example 33: (E)-4-chloro-N-(4-(4-fluorostyryl)-7-morpholino-5,8-dioxo-5,8-dihydroquinolin-6-yl) butanamide (33). Following general protocol H. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (4 mL), morpholine (2.0 mmol, 170 mg) was added and the resulting red-brown solution was stirred at 50 °C until complete disappearance of the starting material (8 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC afford pure product (E)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperidin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide as a dark red solid (9.4 mg, 0.02 mmol, 39%), (HPLC purity at 254nm, 99.5%). ^1H NMR (400 MHz, DMSO) δ 9.43 (s, 1H), 8.86 (d, J = 5.1 Hz, 1H), 8.27 (d, J = 16.5 Hz, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.69 (dd, J = 8.8, 5.6 Hz, 2H), 7.50 (d, J = 16.3 Hz, 1H), 7.31 (t, J = 8.9 Hz, 2H), 3.98 (d, J = 13.5 Hz, 2H), 3.75 – 3.60 (m, 4H), 3.22 – 3.03 (m, 4H), 2.71 – 2.64 (m, 1H), 2.38 – 2.30 (m, 1H). 1.99 – 1.92 (m, 2H). LCMS (ESI) 484.14 $[M + H]^+$.

Example 34: (E)-4-chloro-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)butanamide (34). Following general protocol H. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (2 mL), 1-methylpiperazine (2.0 mmol,

200.3 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (4 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (*E*)-4-chloro-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)butanamide as a dark red solid (12.9 mg, 0.026 mmol, 52%), (HPLC purity at 254nm, 98.8%). ¹H NMR (300 MHz, CDCl₃-d) δ 8.89 (d, *J* = 5.5 Hz, 1H), 8.31 (d, *J* = 16.0 Hz, 1H), 7.81 (d, *J* = 5.2 Hz, 1H), 7.76 (s, 1H), 7.69 – 7.58 (m, 2H), 7.28 – 7.12 (m, 3H), 3.71 (t, *J* = 5.9 Hz, 4H), 3.17– 3.05 (m, 2H), 2.89 (s, 3H), 2.75 (t, *J* = 7.0 Hz, 2H), 2.62 – 2.45 (m, 4H), 2.27 – 2.16 (m, 2H). LCMS (ESI) 497.17 [M + H]⁺.

Example 35: (*E*)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperazin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide (35). Following general protocol H. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (2 mL), 1-methylpiperazine (2.0 mmol, 200.3 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (2 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (*E*)-4-chloro-N-(4-(4-fluorostyryl)-5,8-dioxo-7-(piperazin-1-yl)-5,8-dihydroquinolin-6-yl)butanamide as a dark red solid (18.3 mg, 0.038 mmol, 76%), (HPLC purity at 254nm, 100%). ¹H NMR (400 MHz, DMSO) δ 9.53 (s, 1H), 8.88 (d, *J* = 5.2 Hz, 1H), 8.23 (d, *J* = 16.4 Hz, 1H), 8.04 (d, *J* = 5.2 Hz, 1H), 7.69 (dd, *J* = 8.5, 5.7 Hz, 2H), 7.52 (d, *J* = 16.3 Hz, 1H), 7.32 (t, *J* = 8.8 Hz, 2H), 3.74 (t, *J* = 6.6 Hz, 2H), 3.47 (d, *J* = 5.1 Hz, 4H), 3.23 (s, 4H), 2.61 (d, *J* = 7.4 Hz, 2H), 2.05 (s, 2H). LCMS (ESI) 483.15 [M + H]⁺.

Example 36: (*E*)-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)-4-(4-methylpiperazin-1-yl)butanamide (36). Following general protocol I. To a solution of the **1-12** (0.05 mmol, 20 mg) dissolved in dry chloroform (2 mL), 1-methylpiperazine (2.0 mmol, 200.3 mg) was added and the resulting red-brown solution was stirred at reflux for overnight until complete disappearance of the starting material (TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (*E*)-N-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)-4-(4-methylpiperazin-1-yl)butanamide as a dark red solid (17.6 mg, 63%), (HPLC purity at 254nm, 100%). ¹H NMR (400 MHz, Acetone) δ 8.86 (d, *J* = 5.1 Hz, 1H), 8.36 (d, *J* = 16.4 Hz, 1H), 8.00 (d, *J* = 5.1 Hz, 1H), 7.74 (dd, *J* = 8.7, 5.5 Hz, 2H), 7.48 (d, *J* = 16.3 Hz, 1H), 7.25 (t, *J* = 8.8 Hz, 2H),

3.76 (s, 6H), 3.57 – 3.41 (m, 10H), 3.14 (dd, $J = 10.0, 5.4$ Hz, 2H), 2.98 (s, 3H), 2.85 (s, 3H), 2.77 (t, $J = 6.9$ Hz, 2H), 2.24 – 2.20 (m, 1H), 1.93 – 1.89 (m, 1H). or ^1H NMR (400 MHz, MeOD) δ 8.82 (d, $J = 5.2$ Hz, 1H), 8.37 (d, $J = 16.4$ Hz, 1H), 8.06 (d, $J = 5.2$ Hz, 1H), 7.72 (dd, $J = 8.2, 5.6$ Hz, 2H), 7.47 (d, $J = 16.4$ Hz, 1H), 7.20 (t, $J = 8.6$ Hz, 2H), 3.83 (s, 2H), 3.53 (d, $J = 30.2$ Hz, 6H), 3.15 (s, 6H), 2.99 (s, 3H), 2.95 – 2.88 (m, 2H), 2.88 – 2.78 (m, 2H), 2.82 (s, 3H), 2.70 (t, $J = 6.8$ Hz, 2H), 2.09 – 1.99 (m, 2H).

Example 37: (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dimethoxyquinolin-6-yl)pentanamide (37).

Following general protocol F. To a refluxed solution of methanol (8 mL), glacial acetic acid (1 mL) and water (1 mL) were added in succession compound **1-9** (200 mg, 0.59 mmol) and iron powder (332 mg, 5.9 mmol). The mixture was refluxed for another 30 min with vigorous stirring. The reaction solution was filtered through celite. The organic phase of the filtrate was removed in vacuo and the residue was added saturated aqueous K_2CO_3 solution (20 mL). The resulting mixture was extracted with ethyl acetate, and the organic phase was washed with H_2O , dried over Na_2SO_4 , and concentrated to provide the crude amino product **1-10**, which were pure enough to proceed to the next step of reaction. All the solid products obtained were dissolved in anhydrous Dichloromethane solution, followed by trimethylamine (571mg, 4.76 mmol). The mixture was cooled to 0°C and was added Pentanoyl chloride (419 mg, 2.97 mmol) dropwise. After 1h of stirring at 0°C , the temperature was raised to room temperature and the stirring was continued for overnight. After removal of the solvent in vacuo, the residue was purified by column chromatography to give (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dimethoxyquinolin-6-yl)pentanamide (180.5 mg, 75%) as a yellow solid. ^1H NMR (300 MHz, CDCl_3) δ 9.07 (s, 1H), 8.54 (s, 1H), 8.29 (d, $J = 16.0$ Hz, 2H), 7.74 (s, 1H), 7.67 (dd, $J = 8.6, 5.4$ Hz, 2H), 7.32 (d, $J = 16.2$ Hz, 1H), 7.19 (t, $J = 8.5$ Hz, 2H), 4.09 (s, 3H), 3.66 (s, 3H), 2.57 (t, $J = 7.5$ Hz, 2H), 1.86 – 1.73 (m, 2H), 1.49 (dd, $J = 15.1, 7.5$ Hz, 2H), 1.01 (t, $J = 7.3$ Hz, 3H).

Example 38: (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide (38). Following general protocol G. A solution of **37** (13 mg, 0.032 mmol) in (7:3) acetonitrile:water (1 mL) was cooled at 0°C in an ice bath, and a solution of ceric ammonium nitrate (2.7 eq., 52 mg, 0.09 mmol) in (9:1) acetonitrile:water (1 mL) was added dropwise. The reaction mixture was stirred for 15 min, then poured into ice/water and extracted (5 times) with CH_2Cl_2 . The organic layer was washed (5 times) with water, dried over anhydrous Na_2SO_4 and concentrated to dryness and resulting crude material was purified by

HPLC to afford pure product (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide as a dark red solid (9.4 mg, 78%), (HPLC purity at 254nm, 100%). ¹H NMR (300 MHz, CDCl₃) δ 8.97 (d, *J* = 5.1 Hz, 1H), 8.41 (s, 1H), 8.27 (d, *J* = 16.1 Hz, 1H), 8.05 (s, 1H), 7.81 (d, *J* = 5.1 Hz, 1H), 7.69 – 7.60 (m, 2H), 7.16 (t, *J* = 8.6 Hz, 2H), 2.55 – 2.47 (m, 2H), 1.79 – 1.70 (m, 2H), 1.49 – 1.39 (m, 2H), 0.98 (t, *J* = 7.3 Hz, 3H).

Example 39: (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)pentanamide (**39**). Following general protocol H. To a solution of the **38** (0.05 mmol, 17 mg) dissolved in dry chloroform (2 mL), pyrrolidine (2.0 mmol, 142 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (0.5 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (*E*)-*N*-(4-(4-fluorostyryl)-5,8-dioxo-7-(pyrrolidin-1-yl)-5,8-dihydroquinolin-6-yl)pentanamide as a dark red solid (14.8 mg, 66%), (HPLC purity at 254nm, 97.9%). ¹H NMR (300 MHz, CDCl₃) δ 8.76 (d, *J* = 5.2 Hz, 1H), 8.44 (d, *J* = 16.4 Hz, 1H), 7.72 (s, 1H), 7.65 (d, *J* = 1.5 Hz, 1H), 7.48 (dd, *J* = 3.0, 1.5 Hz, 2H), 7.20 – 7.06 (m, 3H), 3.64 (d, *J* = 2.6 Hz, 4H), 2.48 (dd, *J* = 13.7, 5.9 Hz, 2H), 1.99 – 1.86 (m, 4H), 1.72 (dt, *J* = 15.3, 7.7 Hz, 2H), 1.42 (dd, *J* = 14.8, 7.4 Hz, 2H), 1.03 – 0.91 (m, 3H).

Example 40: (*E*)-*N*-(4-(4-fluorostyryl)-7-morpholino-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide (**40**). Following general protocol H. To a solution of the **38** (0.05 mmol, 17 mg) dissolved in dry chloroform (4 mL), morpholine (2.0 mmol, 170 mg) was added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (8 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC afford pure product (*E*)-*N*-(4-(4-fluorostyryl)-7-morpholino-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide as a dark red solid (12.3 mg, 53%), (HPLC purity at 254nm, 99%). ¹H NMR (300 MHz, CDCl₃) δ 8.86 (d, *J* = 5.2 Hz, 1H), 8.35 (d, *J* = 16.2 Hz, 1H), 7.77 (d, *J* = 5.1 Hz, 1H), 7.67 – 7.57 (m, 3H), 7.21 (d, *J* = 16.2 Hz, 1H), 7.13 (t, *J* = 8.6 Hz, 2H), 3.91 – 3.81 (m, 4H), 3.54 – 3.44 (m, 4H), 2.56 – 2.45 (m, 2H), 1.81 – 1.66 (m, 2H), 1.44 (dd, *J* = 15.0, 7.4 Hz, 2H), 0.98 (t, *J* = 7.3 Hz, 3H).

Example 41: (*E*)-*N*-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide (**41**). Following general protocol H. To a solution of the **38** (0.05 mmol, 17 mg) dissolved in dry chloroform (2 mL), 1-methylpiperazine (2.0 mmol, 200.3 mg) was

added and the resulting red-brown solution was stirred at room temperature until complete disappearance of the starting material (4 h, TLC analysis). The resulting solution was evaporated under reduced pressure and resulting crude material was purified by HPLC to afford pure product (*E*)-*N*-(4-(4-fluorostyryl)-7-(4-methylpiperazin-1-yl)-5,8-dioxo-5,8-dihydroquinolin-6-yl)pentanamide as a dark red solid (17.6 mg, 74%), (HPLC purity at 254nm, 97.6%). ¹H NMR (300 MHz, CDCl₃) δ 8.83 (d, *J* = 5.2 Hz, 1H), 8.32 (d, *J* = 16.4 Hz, 1H), 7.73 (d, *J* = 5.3 Hz, 1H), 7.66 – 7.56 (m, 3H), 7.23 – 7.08 (m, 3H), 3.60 – 3.51 (m, 4H), 2.84 (s, 4H), 2.52 (s, 3H), 2.47 (d, *J* = 8.0 Hz, 2H), 1.70 (d, *J* = 7.6 Hz, 2H), 1.48 – 1.35 (m, 2H), 0.95 (dd, *J* = 13.9, 6.7 Hz, 3H).

Example 42: 9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (42). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)aniline (19.1 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (9.7 mg, 27% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 9.13 (d, *J* = 5.0 Hz, 1H), 8.85 (d, *J* = 8.4 Hz, 1H), 8.24 (d, *J* = 9.5 Hz, 1H), 8.11 – 7.94 (m, 2H), 7.58 (s, 1H), 3.91 (s, 4H), 3.52 (s, 4H), 3.02 (s, 3H). LCMS (ESI) 360.00 [M + H]⁺. HPLC purity at 254 nm, 99.2%.

Example 43: 7-methoxy-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (43). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 2-methoxy-4-(4-methylpiperazin-1-yl)aniline (22.1 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 7-methoxy-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (19.1 mg, 49% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 9.13 (s, 1H), 8.82 (d, *J* = 6.9 Hz, 1H), 8.03 (d, *J* = 7.6 Hz, 1H), 7.12 (s, 1H),

6.93 (s, 1H), 4.06 (s, 3H), 3.59 (s, 8H), 3.09 (s, 3H). LCMS (ESI) 390.10 [M + H]⁺. HPLC purity at 254 nm, 99.3%.

Example 44: 2-methyl-9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile (44). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 5-amino-2-(4-methylpiperazin-1-yl)benzonitrile (21.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-methyl-9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile was recovered as a dark purple solid (19.9 mg, 50% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.72 (d, *J* = 8.1 Hz, 1H), 8.36 (d, *J* = 9.5 Hz, 1H), 8.00 (d, *J* = 9.5 Hz, 1H), 7.89 (d, *J* = 8.2 Hz, 1H), 3.82 – 3.46 (m, 6H), 3.37 (s, 2H), 3.09 (s, 3H), 2.84 (s, 3H). LCMS (ESI) 399.05 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 45: 9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile (45). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 5-amino-2-(4-methylpiperazin-1-yl)benzonitrile (21.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile was recovered as a dark purple solid (11.1 mg, 29% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (dd, *J* = 4.6, 1.7 Hz, 1H), 9.07 (s, 1H), 8.70 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.06 (s, 1H), 8.00 (dd, *J* = 7.9, 4.6 Hz, 1H), 4.00 (s, 6H), 2.90 (d, *J* = 17.4 Hz, 5H). LCMS (ESI) 385.25 [M + H]⁺. HPLC purity at 254 nm, 98.5%.

Example 46: 9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-8-carbonitrile (46). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.)

and 5-amino-2-(4-methylpiperazin-1-yl)benzonitrile (21.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-8-carbonitrile was recovered as a dark purple solid (8.4 mg, 22% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (dd, *J* = 4.6, 1.7 Hz, 1H), 9.07 (s, 1H), 8.70 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.06 (s, 1H), 8.00 (dd, *J* = 7.9, 4.6 Hz, 1H), 4.00 (s, 6H), 2.90 (d, *J* = 17.4 Hz, 5H). LCMS (ESI) 384.95 [M + H]⁺. HPLC purity at 254 nm, 98.1%.

Example 47: 9-(4-(methylsulfonyl)piperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile (47). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 5-amino-2-(4-(methylsulfonyl)piperazin-1-yl)benzonitrile (28.0 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-(methylsulfonyl)piperazin-1-yl)-5,12-dioxo-5,12-dihydropyrido[2,3-b]phenazine-10-carbonitrile was recovered as a dark purple solid (22.0 mg, 49% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.16 (dd, *J* = 4.6, 1.6 Hz, 1H), 8.67 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.42 (d, *J* = 9.8 Hz, 1H), 8.03 (d, *J* = 9.5 Hz, 1H), 7.98 (dd, *J* = 7.8, 4.6 Hz, 1H), 3.98 (s, 4H), 3.42 (s, 4H), 3.00 (s, 3H). LCMS (ESI) 448.90 [M + H]⁺. HPLC purity at 254 nm, 96.0%.

Example 48: 9-(4-ethylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (48). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-ethylpiperazin-1-yl)aniline (20.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-

(4-ethylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (11.6 mg, 31% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.14 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.66 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.26 (d, *J* = 9.5 Hz, 1H), 8.08 (d, *J* = 2.7 Hz, 1H), 7.96 (dd, *J* = 7.9, 4.6 Hz, 1H), 7.67 (d, *J* = 2.7 Hz, 1H), 4.44 (s, 2H), 3.66 (s, 4H), 3.24 (q, *J* = 7.1 Hz, 4H), 1.29 (t, *J* = 7.3 Hz, 3H). LCMS (ESI) 374.05 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 49: 9-(4-cyclopropylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (49).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-cyclopropylpiperazin-1-yl)aniline (21.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-cyclopropylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (23.5 mg, 61% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.13 (dd, *J* = 4.6, 1.6 Hz, 1H), 8.85 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.24 (d, *J* = 9.5 Hz, 1H), 8.03 (ddd, *J* = 12.6, 8.8, 3.7 Hz, 2H), 7.58 (d, *J* = 2.7 Hz, 1H), 3.94 (s, 4H), 3.69 (s, 4H), 3.04 – 2.90 (m, 1H), 1.16 – 1.02 (m, 4H). LCMS (ESI) 386.05 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 50: 9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (50). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (14.5 mg, 34% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.15 (dd, *J* = 4.6, 1.5 Hz, 1H), 8.85 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.39 (d, *J* = 9.5 Hz, 1H), 8.10 (d, *J* = 9.6 Hz, 1H), 8.02 (dd, *J* = 8.0, 4.7 Hz, 1H), 4.01 – 3.40 (m, 8H), 3.08 (s, 3H). LCMS (ESI) 428.10 [M + H]⁺. HPLC purity at 254 nm, 99.1%.

Example 51: 9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (51). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-methyl-9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b] phenazine-5,12-dione was recovered as a dark purple solid (7.1 mg, 16% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 9.18 (dd, $J = 4.6, 1.6$ Hz, 1H), 8.89 (dd, $J = 8.0, 1.7$ Hz, 1H), 8.80 (s, 1H), 8.40 (s, 1H), 8.05 (dd, $J = 8.0, 4.7$ Hz, 1H), 3.380-3.71 (m, 2H), 3.65-3.57 (m, 2H), 3.50-3.39 (m, 4H), 3.08 (s, 3H). LCMS (ESI) 428.10 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 99.8%.

Example 52: 2-methyl-9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (52). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-methyl-9-(4-methylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b] phenazine-5,12-dione was recovered as a dark purple solid (11.0 mg, 25% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 8.69 (d, $J = 8.1$ Hz, 1H), 8.39 (d, $J = 9.5$ Hz, 1H), 8.10 (d, $J = 9.5$ Hz, 1H), 7.87 (d, $J = 8.1$ Hz, 1H), 3.93 (s, 2H), 3.71 (s, 4H), 3.53 – 3.38 (m, 2H), 3.08 (s, 3H), 2.83 (s, 3H). LCMS (ESI) 442.10 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 95.8%.

Example 53: 2-methyl-9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (53). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)aniline (25.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was

removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-methyl-9-(4-methylpiperazin-1-yl)-8-(trifluoromethyl) pyrido[2,3-b] phenazine-5,12-dione was recovered as a dark purple solid (7.1 mg, 16% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.81 (s, 1H), 8.75 (d, *J* = 8.1 Hz, 1H), 8.40 (s, 1H), 7.91 (d, *J* = 8.2 Hz, 1H), 3.72 (s, 2H), 3.61 (s, 2H), 3.42 (d, *J* = 8.4 Hz, 4H), 3.08 (s, 3H), 2.85 (s, 3H). LCMS (ESI) 441.95 [M + H]⁺. HPLC purity at 254 nm, 98.7%.

Example 54: 9-(4-cyclopropylpiperazin-1-yl)-2-methylpyrido[2,3-b]phenazine-5,12-dione (54). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-cyclopropylpiperazin-1-yl)aniline (21.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-cyclopropylpiperazin-1-yl)-2-methylpyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (21.9 mg, 55% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.70 (d, *J* = 8.1 Hz, 1H), 8.23 (d, *J* = 9.5 Hz, 1H), 8.04 (dd, *J* = 9.6, 2.8 Hz, 1H), 7.87 (d, *J* = 8.2 Hz, 1H), 7.58 (d, *J* = 2.7 Hz, 1H), 3.92 (s, 4H), 3.64 (s, 4H), 2.90 (s, 1H), 2.83 (s, 3H), 1.05 (dd, *J* = 11.1, 6.1 Hz, 4H). LCMS (ESI) 400.15 [M + H]⁺. HPLC purity at 254 nm, 99.4%.

Example 55: 10-fluoro-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (55). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 3-fluoro-4-(4-methylpiperazin-1-yl)aniline (20.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 10-fluoro-9-(4-methylpiperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (7.9 mg, 21% yield). ¹H NMR (400 MHz,

Methanol-*d*₄) δ 9.15 (dd, *J* = 4.8, 1.7 Hz, 1H), 8.87 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.18 (dd, *J* = 9.5, 1.4 Hz, 1H), 8.10 – 7.96 (m, 2H), 4.15 (s, 2H), 3.81 – 3.44 (m, 6H), 3.07 (s, 3H). LCMS (ESI) 378.10 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 56: 10-chloro-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (56).

- 5 Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 3-chloro-4-(4-methylpiperazin-1-yl)aniline (22.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μ L) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture
10 solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 10-chloro-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (13.0 mg, 33% yield). ¹H NMR (499 MHz, Methanol-*d*₄) δ 9.14 (d, *J* = 3.3 Hz, 1H), 8.85 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.30 (d, *J* = 9.3 Hz, 1H), 8.04 (d, *J* = 9.3 Hz, 1H), 8.01 (dd, *J* = 8.0, 4.7 Hz, 1H), 4.03 (s, 2H), 3.72 (s, 2H), 3.49
15 (s, 4H), 3.06 (s, 3H). ¹⁹F NMR (470 MHz, Methanol-*d*₄) δ -76.99. LCMS (ESI) 393.90 [M + H]⁺. HPLC purity at 254 nm, 99.0%.

Example 57: 9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (57).

- 20 Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-(methylsulfonyl)piperazin-1-yl)aniline (25.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μ L) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered
25 precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (17.3 mg, 41% yield). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.24 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.84 (dd, *J* = 8.0, 1.8 Hz, 1H), 8.34 (d, *J* = 9.6 Hz, 1H), 7.87 (dd, *J* = 8.0, 4.6 Hz, 1H), 7.79 (dd, *J* = 9.6, 2.9 Hz, 1H), 7.63
30 (d, *J* = 3.0 Hz, 1H), 3.85 – 3.68 (m, 4H), 3.56 – 3.39 (m, 4H), 2.89 (s, 3H). LCMS (ESI) 424.10 [M + H]⁺. HPLC purity at 254 nm, 99.2%.

Example 58: 2-methyl-9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (58). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-

dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-(methylsulfonyl)piperazin-1-yl)aniline (25.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-methyl-9-(4-(methylsulfonyl)piperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (20.1 mg, 46% yield). ^1H NMR (300 MHz, Chloroform-*d*) δ 8.69 (d, $J = 7.7$ Hz, 1H), 8.32 (d, $J = 9.5$ Hz, 1H), 7.78 (s, 1H), 7.72 – 7.62 (m, 2H), 3.72 (s, 4H), 3.49 (s, 4H), 2.88 (s, 3H), 2.86 (s, 3H). LCMS (ESI) 438.05 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 100%.

Example 59: 10-chloro-2-methyl-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione (59). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 3-chloro-4-(4-methylpiperazin-1-yl)aniline (22.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 10-chloro-2-methyl-9-(4-methylpiperazin-1-yl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (15.9 mg, 39% yield). ^1H NMR (300 MHz, DMSO-*d*₆) δ 8.57 (d, $J = 8.0$ Hz, 1H), 8.35 (d, $J = 9.2$ Hz, 1H), 8.09 (d, $J = 9.4$ Hz, 1H), 7.85 (d, $J = 8.1$ Hz, 1H), 3.92 (s, 4H), 3.37 (s, 4H), 2.95 (s, 3H), 2.76 (s, 3H). LCMS (ESI) 408.05 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 95.5%.

Example 60: 9-((4-ethylpiperazin-1-yl)methyl)-2-methylpyrido[2,3-*b*]phenazine-5,12-dione (60). Following general protocol J. A solution of 6,7-dichloro-2-methylquinoline-5,8-dione (0.1 equiv, 24 mg), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-((4-ethylpiperazin-1-yl)methyl)aniline (21.9 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-((4-ethylpiperazin-1-yl)methyl)-2-methylpyrido[2,3-

b]phenazine-5,12-dione was recovered as a dark purple solid (9.6 mg, 24% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 8.74 (d, *J* = 8.1 Hz, 1H), 8.42 (d, *J* = 8.6 Hz, 2H), 8.19 (dd, *J* = 8.9, 1.7 Hz, 1H), 7.90 (d, *J* = 8.1 Hz, 1H), 4.02 (s, 2H), 3.72 – 3.46 (m, 2H), 3.30 – 3.13 (m, 6H), 2.84 (s, 3H), 2.74 – 2.55 (m, 2H), 1.39 (t, *J* = 7.3 Hz, 3H). LCMS (ESI) 402.20 [M + H]⁺. HPLC purity at 254 nm, 99.5%.

Example 61: 9-(4-methylpiperazine-1-carbonyl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (61). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and (4-amino-2-(trifluoromethyl)phenyl)(4-ethylpiperazin-1-yl)methanone (30.1 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazine-1-carbonyl)-8-(trifluoromethyl) pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (10.0 mg, 22% yield). ¹H NMR (300 MHz, Methanol-*d*₄) δ 9.19 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.99 – 8.85 (m, 2H), 8.64 (s, 1H), 8.06 (dd, *J* = 8.0, 4.7 Hz, 1H), 3.67 (d, *J* = 74.0 Hz, 8H), 3.03 (s, 3H). LCMS (ESI) 456.05 [M + H]⁺. HPLC purity at 254 nm, 98.8%.

Example 62: 9-morpholino-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (62). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-morpholino-3-(trifluoromethyl)aniline (24.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-morpholino-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (12 mg, 29% yield). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.25 (d, *J* = 4.6 Hz, 1H), 8.83 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.42 (d, *J* = 9.6 Hz, 1H), 7.95 – 7.79 (m, 2H), 4.01 – 3.89 (m, 4H), 3.58 (d, *J* = 5.1 Hz, 4H). LCMS (ESI) 415.00 [M + H]⁺. HPLC purity at 254 nm, 99.7%.

Example 63: 9-morpholino-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (63).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-morpholino-3-(trifluoromethyl)aniline (24.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-morpholino-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (7.9 mg, 19% yield). ^1H NMR (300 MHz, Chloroform- d) δ 9.30 (d, $J = 2.7$ Hz, 1H), 8.93 – 8.83 (m, 2H), 8.19 (s, 1H), 7.93 (dd, $J = 8.0$, 4.6 Hz, 1H), 4.05 – 3.90 (m, 4H), 3.34 – 3.20 (m, 4H). LCMS (ESI) 414.95 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 98.7%.

Example 64: 9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (64). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperidin-1-yl)aniline (19.0 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (19.3 mg, 54% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 9.10 (s, 1H), 8.82 (d, $J = 7.7$ Hz, 1H), 8.13 (d, $J = 9.6$ Hz, 1H), 8.00 (d, $J = 9.3$ Hz, 2H), 7.43 (d, $J = 2.7$ Hz, 1H), 4.29 (d, $J = 13.2$ Hz, 2H), 3.27 – 3.11 (m, 2H), 1.90 (d, $J = 13.6$ Hz, 2H), 1.45 – 1.27 (m, 3H), 1.04 (d, $J = 6.4$ Hz, 3H). LCMS (ESI) 359.00 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 100%.

Example 65: 9-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (65). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)aniline (25.8 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled,

the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (20.9 mg, 49% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.13 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.90 – 8.77 (m, 1H), 8.34 (s, 1H), 8.02 (dd, *J* = 7.9, 4.6 Hz, 1H), 7.70 (s, 1H), 3.61 (s, 8H), 3.12 – 3.01 (m, 2H). LCMS (ESI) 428.00 [M + H]⁺. HPLC purity at 254 nm, 99.8%.

Example 66: 9-morpholino-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (66).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-morpholino-2-(trifluoromethyl)aniline (24.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-morpholino-7-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (16.6 mg, 40% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.12 (s, 1H), 8.84 (d, *J* = 7.9 Hz, 1H), 8.31 (d, *J* = 2.4 Hz, 1H), 8.00 (dd, *J* = 8.1, 4.1 Hz, 1H), 7.66 (d, *J* = 2.8 Hz, 1H), 4.01 – 3.91 (m, 2H), 3.88 (dt, *J* = 10.6, 4.7 Hz, 2H), 3.74 (t, *J* = 5.7 Hz, 1H), 3.66 (t, *J* = 4.9 Hz, 2H), 3.45 – 3.38 (m, 1H). LCMS (ESI) 415.05 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 68: 9-(4-(tert-butyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (68).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-(tert-butyl)piperazin-1-yl)aniline (23.3 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-(tert-butyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (12 mg, 30% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.14 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.85 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.24 (d, *J* = 9.5 Hz, 1H), 8.10 – 7.97 (m, 2H), 7.57 (d, *J* = 2.8 Hz, 1H), 4.50 (d, *J* = 21.8 Hz, 2H), 3.81 (d, *J* = 32.5 Hz, 2H),

3.61 – 3.40 (m, 4H), 1.55 (s, 9H). LCMS (ESI) 402.20 [M + H]⁺. HPLC purity at 254 nm, 98.4%.

Example 69: 9-(4-(4-methoxyphenyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (69). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1

equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-(4-methoxyphenyl)piperazin-1-yl)aniline (28.3 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-(4-methoxyphenyl)piperazin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (22.0 mg, 49% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.20 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.81 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.29 (d, *J* = 9.6 Hz, 1H), 7.92 – 7.78 (m, 2H), 7.61 (d, *J* = 2.9 Hz, 1H), 7.03 – 6.92 (m, 2H), 6.92 – 6.82 (m, 2H), 3.79 (s, 3H), 3.78 – 3.73 (m, 4H), 3.29 (dd, *J* = 6.4, 3.8 Hz, 4H). LCMS (ESI) 451.90 [M + H]⁺. HPLC purity at 254 nm, 99.3%.

Example 70: 9-((3a*S*,5*S*,7a*S*)-octahydro-7a*H*-2,5-methanoinden-7a-yl)pyrido[2,3-b]phenazine-5,12-dione (70). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-((3a*S*,5*S*,7a*S*)-octahydro-7a*H*-2,5-methanoinden-7a-yl)aniline (22.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-((3a*S*,5*S*,7a*S*)-octahydro-7a*H*-2,5-methanoinden-7a-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (24.1 mg, 61% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.26 (s, 1H), 8.86 (d, *J* = 7.9 Hz, 1H), 8.53 – 8.37 (m, 2H), 8.20 (dd, *J* = 9.0, 2.2 Hz, 1H), 7.89 (dd, *J* = 7.8, 4.3 Hz, 1H), 2.21 (s, 3H), 2.15 (s, 2H), 2.07 (d, *J* = 2.9 Hz, 4H), 1.85 (q, *J* = 12.6 Hz, 6H). LCMS (ESI) 396.25 [M + H]⁺. HPLC purity at 254 nm, 95.8%.

Example 71: 9-(thiazol-2-yl)pyrido[2,3-b]phenazine-5,12-dione (71). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(thiazol-2-yl)aniline (17.6 mg, 0.1 mmol) in

ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(thiazol-2-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (22.7 mg, 66% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.26 (dd, *J* = 4.6, 1.8 Hz, 1H), 9.01 (d, *J* = 2.0 Hz, 1H), 8.83 (ddd, *J* = 15.7, 8.5, 1.9 Hz, 2H), 8.55 (d, *J* = 8.9 Hz, 1H), 8.04 (d, *J* = 3.2 Hz, 1H), 7.88 (dd, *J* = 8.0, 4.5 Hz, 1H), 7.56 (d, *J* = 3.2 Hz, 1H). LCMS (ESI) 344.95 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 72: 5,12-dioxo-*N,N*-dipropyl-5,12-dihydropyrido[2,3-*b*]phenazine-9-sulfonamide (72). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-amino-*N,N*-dipropylbenzenesulfonamide (25.6 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 5,12-dioxo-*N,N*-dipropyl-5,12-dihydropyrido[2,3-*b*]phenazine-9-sulfonamide was recovered as a dark purple solid (21.6 mg, 51% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.30 (dd, *J* = 4.6, 1.8 Hz, 1H), 9.01 (dd, *J* = 2.0, 0.6 Hz, 1H), 8.88 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.63 (dd, *J* = 9.0, 0.6 Hz, 1H), 8.38 (dd, *J* = 8.9, 2.0 Hz, 1H), 7.92 (dd, *J* = 8.0, 4.6 Hz, 1H), 3.31 – 3.17 (m, 4H), 1.70 – 1.53 (m, 4H), 0.90 (t, *J* = 7.4 Hz, 6H). LCMS (ESI) 424.95 [M + H]⁺. HPLC purity at 254 nm, 96.8%.

Example 73: 9-cyclopropylpyrido[2,3-*b*]phenazine-5,12-dione (73). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-cyclopropylaniline (13.3 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 µL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-cyclopropylpyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (21.0

mg, 70% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.25 (dd, *J* = 4.6, 1.8 Hz, 1H), 8.85 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.38 (d, *J* = 8.9 Hz, 1H), 8.13 (d, *J* = 2.0 Hz, 1H), 7.87 (dd, *J* = 8.0, 4.5 Hz, 1H), 7.79 (dd, *J* = 8.9, 2.0 Hz, 1H), 2.22 (tt, *J* = 8.2, 5.0 Hz, 1H), 1.37 – 1.24 (m, 2H), 1.12 – 0.94 (m, 2H). LCMS (ESI) 302.00 [M + H]⁺. HPLC purity at 254 nm, 95.9%.

- 5 **Example 74: 9-cyclohexylpyrido[2,3-*b*]phenazine-5,12-dione (74).** Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-cyclohexylaniline (17.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added
10 to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-cyclohexylpyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (23.3 mg, 68% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.25 (dd, *J* = 4.6, 1.8 Hz, 1H), 8.85 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.41 (d, *J* = 8.8 Hz, 1H), 8.34 (dt, *J* = 2.1, 0.7 Hz, 1H), 7.96 (dd, *J* = 9.0, 1.9 Hz, 1H), 7.87 (dd, *J* = 7.9, 4.5 Hz, 1H), 2.96 – 2.75 (m, 1H), 2.07 (d, *J* = 12.0 Hz, 2H), 1.95 (d, *J* = 12.5 Hz, 2H), 1.84 (dd, *J* = 12.9, 3.1 Hz, 1H), 1.63 – 1.43 (m, 4H), 1.40 – 1.27 (m, 1H). LCMS (ESI) 344.05 [M + H]⁺. HPLC purity at 254 nm, 100%.

Example 75: 9-((2-(diethylamino)ethyl)amino)pyrido[2,3-*b*]phenazine-5,12-dione (75).

- 20 Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and *N*¹-(2-(diethylamino)ethyl)benzene-1,4-diamine (20.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction
25 system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-((2-(diethylamino)ethyl)amino)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (7.1 mg, 19% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.18 – 9.08 (m, 1H),
30 8.84 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.14 (d, *J* = 9.3 Hz, 1H), 8.01 (dd, *J* = 8.0, 4.7 Hz, 1H), 7.61 (dd, *J* = 9.3, 2.6 Hz, 1H), 7.24 (d, *J* = 2.6 Hz, 1H), 3.86 (t, *J* = 6.6 Hz, 4H), 3.55 (t, *J* = 6.6 Hz, 2H), 3.45 – 3.37 (m, 4H), 1.41 (t, *J* = 7.3 Hz, 6H). LCMS (ESI) 376.10 [M + H]⁺. HPLC purity at 254 nm, 97.5%.

Example 76: 2-(4-methylpiperazin-1-yl)benzo[b]phenazine-6,11-dione (76). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-methylpiperazin-1-yl)aniline (19.1 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-(4-methylpiperazin-1-yl)benzo[b]phenazine-6,11-dione was recovered as a dark purple solid (26.9 mg, 75% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 8.44 (ddd, $J = 5.5, 4.2, 2.9$ Hz, 2H), 8.21 (d, $J = 9.5$ Hz, 1H), 8.08 – 7.91 (m, 3H), 7.53 (d, $J = 2.9$ Hz, 1H), 4.65- 4.21 (m, 2H), 3.92 – 3.37 (m, 4H), 2.68 (s, 3H). LCMS (ESI) 359.15 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 98.8%.

Example 77: 2-(4-(tert-butyl)piperazin-1-yl)benzo[b]phenazine-6,11-dione (77). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(4-(tert-butyl)piperazin-1-yl)aniline (23.3 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 2-(4-(tert-butyl)piperazin-1-yl)benzo[b]phenazine-6,11-dione was recovered as a dark purple solid (28.8 mg, 72% yield). ^1H NMR (400 MHz, Chloroform- d) δ 8.49 (t, $J = 7.4$ Hz, 2H), 8.36 (d, $J = 9.5$ Hz, 1H), 7.99 – 7.86 (m, 2H), 7.70 (d, $J = 9.5$ Hz, 1H), 7.63 (s, 1H), 4.15 (s, 2H), 3.83 (s, 4H), 3.05 (s, 2H), 1.52 (s, 9H). LCMS (ESI) 401.05 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 99.6%.

Example 78: 9-(1-methylpiperidin-4-yl)pyrido[2,3-b]phenazine-5,12-dione (78). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(1-methylpiperidin-4-yl)aniline (19.1 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene

chloride and concentrated, and then the residue was purified by column chromatography, 9-(1-methylpiperidin-4-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (16.5 mg, 46% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.17 (dd, *J* = 4.6, 1.7 Hz, 1H), 8.70 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.42 (d, *J* = 8.8 Hz, 1H), 8.23 (d, *J* = 2.0 Hz, 1H), 8.08 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.99 (dd, *J* = 7.9, 4.6 Hz, 1H), 3.63 (d, *J* = 12.0 Hz, 2H), 3.58 – 3.39 (m, 3H), 2.88 (s, 3H), 2.26 (d, *J* = 13.8 Hz, 2H), 2.18 – 2.03 (m, 2H). LCMS (ESI) 359.15 [M + H]⁺. HPLC purity at 254 nm, 98.5%.

Example 79: 9-(4-methyl-1,4-diazepan-1-yl)pyrido[2,3-b]phenazine-5,12-dione (79).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(4-methyl-1,4-diazepan-1-yl)aniline (20.5 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-methyl-1,4-diazepan-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (10.8 mg, 29% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.13 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.83 (dd, *J* = 8.0, 1.7 Hz, 1H), 8.14 (d, *J* = 9.6 Hz, 1H), 8.01 (dd, *J* = 8.0, 4.7 Hz, 1H), 7.89 (dd, *J* = 9.6, 2.9 Hz, 1H), 7.34 (d, *J* = 2.8 Hz, 1H), 4.31 – 3.41 (m, 10H), 3.06 (s, 3H). LCMS (ESI) 374.15 [M + H]⁺. HPLC purity at 254 nm, 97.4%.

Example 80: 9-(pyrrolidin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (80).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 4-(pyrrolidin-1-yl)-3-(trifluoromethyl)aniline (23.0 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(pyrrolidin-1-yl)-10-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (7.2 mg, 18% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.11 (d, *J* = 4.5 Hz, 1H), 8.81 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.12 (d, *J* = 9.8 Hz, 1H), 8.03 – 7.91 (m, 2H), 3.76 (s, 4H), 2.14 – 2.03 (m, 4H). LCMS (ESI) 399.00 [M + H]⁺. HPLC purity at 254 nm, 99.2%.

Example 81: 9-(pyrrolidin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione (81).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 4-(pyrrolidin-1-yl)-3-(trifluoromethyl)aniline (23.0 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(pyrrolidin-1-yl)-8-(trifluoromethyl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (6.0 mg, 15% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 9.12 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.84 (dd, $J = 8.0, 1.7$ Hz, 1H), 8.61 (s, 1H), 8.01 (dd, $J = 8.0, 4.7$ Hz, 1H), 7.57 (s, 1H), 3.70 (t, $J = 6.3$ Hz, 4H), 2.23 – 2.08 (m, 4H). LCMS (ESI) 399.00 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 98.4%.

Example 82: 10-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (82).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 3-fluoro-4-(4-methylpiperidin-1-yl)aniline (20.8 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 10-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (13.1 mg, 35% yield). ^1H NMR (400 MHz, Methanol- d_4) δ 9.12 (dd, $J = 4.6, 1.7$ Hz, 1H), 8.85 (dd, $J = 8.0, 1.7$ Hz, 1H), 8.12 – 8.06 (m, 1H), 8.04 – 7.93 (m, 2H), 4.09 (d, $J = 12.8$ Hz, 2H), 3.24 (t, $J = 12.6$ Hz, 2H), 1.88 (d, $J = 13.1$ Hz, 2H), 1.75 (s, 1H), 1.52 – 1.41 (m, 2H), 1.06 (d, $J = 6.5$ Hz, 3H). LCMS (ESI) 377.15 $[\text{M} + \text{H}]^+$. HPLC purity at 254 nm, 98.5%.

Example 83: 8-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione (83).

Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate ($\text{CeCl}_3 \cdot 7 \text{H}_2\text{O}$, 0.11 equiv.) and 3-fluoro-4-(4-methylpiperidin-1-yl)aniline (20.8 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H_2O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture

solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 8-fluoro-9-(4-methylpiperidin-1-yl)pyrido[2,3-b]phenazine-5,12-dione was recovered as a dark purple solid (0.98 mg, 26% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.12 (dd, *J* = 4.7, 1.7 Hz, 1H), 8.82 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.00 (dd, *J* = 7.9, 4.6 Hz, 1H), 7.88 (s, 1H), 7.57 (s, 1H), 3.86 (d, *J* = 12.3 Hz, 2H), 3.03 – 2.80 (m, 2H), 1.86 (d, *J* = 12.9 Hz, 2H), 1.75 – 1.61 (m, 1H), 1.49 (qd, *J* = 12.3, 3.8 Hz, 2H), 1.07 (d, *J* = 6.5 Hz, 3H). LCMS (ESI) 377.15 [*M* + *H*]⁺. HPLC purity at 254 nm, 98.8%.

Example 84: 9-(4-acetylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-*b*]phenazine-5,12-dione (84). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 1-(4-(4-amino-2-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-one (28.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-acetylpiperazin-1-yl)-10-(trifluoromethyl)pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (22.3 mg, 49% yield). ¹H NMR (400 MHz, Chloroform-*d*) δ 9.28 (dd, *J* = 4.6, 1.8 Hz, 1H), 8.85 (dd, *J* = 8.0, 1.8 Hz, 1H), 8.46 (d, *J* = 9.6 Hz, 1H), 7.93 – 7.82 (m, 2H), 3.92 (s, 2H), 3.79 – 3.73 (m, 2H), 3.56 (dd, *J* = 11.6, 6.9 Hz, 2H), 2.23 (s, 3H). LCMS (ESI) 456.10 [*M* + *H*]⁺. HPLC purity at 254 nm, 99.0%.


Example 85: 9-(4-acetylpiperazin-1-yl)-8-(trifluoromethyl)pyrido[2,3-*b*]phenazine-5,12-dione (85). Following general protocol J. A solution of 6,7-dichloro-5,8-quinolinediones (0.1 equiv.), cerium(III) chloride heptahydrate (CeCl₃·7 H₂O, 0.11 equiv.) and 1-(4-(4-amino-2-(trifluoromethyl) phenyl) piperazin-1-yl)ethan-1-one (28.7 mg, 0.1 mmol) in ethanol (2 mL) was stirred at 60-80 °C for 2 h. Next, most of the ethanol was removed under vacuum. Then DMF (2 mL), H₂O (10 μL) and sodium azide (13 mg, 0.2 mmol) were added to above reaction system. The mixture solution was stirred at 90 °C for 2 h. The reaction mixture was chilled, the filtered precipitate was extracted with methylene chloride and concentrated, and then the residue was purified by column chromatography, 9-(4-acetylpiperazin-1-yl)-8-(trifluoromethyl) pyrido[2,3-*b*]phenazine-5,12-dione was recovered as a dark purple solid (21.0 mg, 46% yield). ¹H NMR (400 MHz, Methanol-*d*₄) δ 9.16 (dd, *J* = 4.7, 1.7 Hz, 1H),

8.89 (dd, J = 8.0, 1.7 Hz, 1H), 8.78 (s, 1H), 8.29 (s, 1H), 8.04 (dd, J = 8.0, 4.7 Hz, 1H), 3.86-3.79 (m, 4H), 3.31-3.22 (m, 4H), 2.22 (s, 3H). LCMS (ESI) 456.10 [M + H]⁺. HPLC purity at 254 nm, 99.8%.

5 Example III.


Representative compounds were tested in a panel of 60 cancer cells (NCI 60) at the National Cancer Institute. Growth inhibition are shown in table 2, table 3, table 4, table 5, and Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5.

10 **Table 2.** Growth inhibition (% control) of compound **1** in the NCI60 cell lines.




PANELNME	CELLNAME	GIPRCNT	PANELNME	CELLNAME	GIPRCNT
Leukemia	CCRF-CEM	-18.2389	Melanoma	LOX IMVI	-70.2674
Leukemia	HL-60(TB)	-26.4294	Melanoma	MALME-3M	-96.0656
Leukemia	K-562	-0.83445	Melanoma	M14	-40.5376
Leukemia	MOLT-4	-22.6883	Melanoma	MDA-MB-435	-75.7981
Leukemia	RPMI-8226	-20.7257	Melanoma	SK-MEL-2	-49.6035
Leukemia	SR	-0.81342	Melanoma	SK-MEL-28	-55.0718
Non-Small Cell Lung Cancer	A549/ATCC	74.56334	Melanoma	SK-MEL-5	-91.7268
Non-Small Cell Lung Cancer	EKVX	-82.6636	Melanoma	UACC-257	-62.2412
Non-Small Cell Lung Cancer	HOP-62	83.28052	Melanoma	UACC-62	-45.6278
Non-Small Cell Lung Cancer	HOP-92	-79.9407	Ovarian Cancer	IGROV1	-90.4429
Non-Small Cell Lung Cancer	NCI-H226	85.31879	Ovarian Cancer	OVCAR-3	-98.2241
Non-Small Cell Lung Cancer	NCI-H23	-61.2055	Ovarian Cancer	OVCAR-4	-99.2407
Non-Small Cell Lung Cancer	NCI-H322M	101.8249	Ovarian Cancer	OVCAR-5	-59.8079
Non-Small Cell Lung Cancer	NCI-H460	9.912259	Ovarian Cancer	OVCAR-8	1.948805
Non-Small Cell Lung Cancer	NCI-H522	-59.746	Ovarian Cancer	NCI/ADR-RES	37.87226
Colon Cancer	COLO 205	33.97826	Ovarian Cancer	SK-OV-3	82.66932
Colon Cancer	HCC-2998	61.85349	Renal Cancer	786-0	-72.0362
Colon Cancer	HCT-116	-69.7462	Renal Cancer	A498	80.11417
Colon Cancer	HCT-15	-8.53119	Renal Cancer	ACHN	-93.058
Colon Cancer	HT29	11.1525	Renal Cancer	CAKI-1	-85.6094
Colon Cancer	KM12	82.36567	Renal Cancer	SN12C	-97.4828
Colon Cancer	SW-620	-76.6429	Renal Cancer	TK-10	8.46166
CNS Cancer	SF-268	48.73363	Renal Cancer	UO-31	-100
CNS Cancer	SF-295	78.81483	Prostate Cancer	PC-3	11.82948
CNS Cancer	SF-539	-25.0889	Prostate Cancer	DU-145	-67.5681
CNS Cancer	SNB-19	96.33177	Breast Cancer	MCF7	-58.1831
CNS Cancer	SNB-75	38.01025	Breast Cancer	MDA-MB-231/ATCC	-31.9795

CNS Cancer	U251	-9.87723	Breast Cancer	HS 578T	-16.4793
			Breast Cancer	BT-549	80.51756
			Breast Cancer	T-47D	-32.5382
			Breast Cancer	MDA-MB-468	-73.911

Table 3. Growth inhibition (% control) of compound **13** in the NCI60 cell lines.**13**


5

PANELNME	CELLNAME	GIPRCNT	PANELNME	CELLNAME	GIPRCNT
Leukemia	CCRF-CEM	-6.23727	Melanoma	LOX IMVI	-95.4404
Leukemia	HL-60(TB)	-46.6759	Melanoma	MALME-3M	-75.4881
Leukemia	K-562	-12.2778	Melanoma	M14	73.82868
Leukemia	MOLT-4	-25.588	Melanoma	MDA-MB-435	-99.1118
Leukemia	RPMI-8226	-32.551	Melanoma	SK-MEL-2	68.35914
Leukemia	SR	-5.05435	Melanoma	SK-MEL-28	30.32254
Non-Small Cell Lung Cancer	A549/ATCC	97.63702	Melanoma	SK-MEL-5	10.38648
Non-Small Cell Lung Cancer	EKVX	-81.7903	Melanoma	UACC-257	57.23161
Non-Small Cell Lung Cancer	HOP-62	63.65498	Melanoma	UACC-62	-49.3593
Non-Small Cell Lung Cancer	HOP-92	-86.301	Ovarian Cancer	IGROV1	-83.5269
Non-Small Cell Lung Cancer	NCI-H226	105.4813	Ovarian Cancer	OVCAR-3	-100
Non-Small Cell Lung Cancer	NCI-H23	16.65413	Ovarian Cancer	OVCAR-4	-100
Non-Small Cell Lung Cancer	NCI-H322M	97.34827	Ovarian Cancer	OVCAR-5	-7.54758
Non-Small Cell Lung Cancer	NCI-H460	97.22202	Ovarian Cancer	OVCAR-8	-62.572
Non-Small Cell Lung Cancer	NCI-H522	-63.7561	Ovarian Cancer	NCI/ADR-RES	27.60809
Colon Cancer	COLO 205	82.4617	Ovarian Cancer	SK-OV-3	89.88163
Colon Cancer	HCC-2998	95.31216	Renal Cancer	786-0	52.17685
Colon Cancer	HCT-116	-64.939	Renal Cancer	A498	100.8258
Colon Cancer	HCT-15	70.43851	Renal Cancer	ACHN	-93.75
Colon Cancer	HT29	66.44319	Renal Cancer	CAKI-1	-100
Colon Cancer	KM12	92.08078	Renal Cancer	RXF 393	62.77679
Colon Cancer	SW-620	-69.7878	Renal Cancer	SN12C	-88.5465
CNS Cancer	SF-268	77.71986	Renal Cancer	TK-10	100.0838
CNS Cancer	SF-295	99.36131	Renal Cancer	UO-31	-97.3532
CNS Cancer	SF-539	-24.5048	Prostate Cancer	PC-3	68.66255
CNS Cancer	SNB-19	94.60122	Prostate Cancer	DU-145	-18.6864
CNS Cancer	SNB-75	-53.8363	Breast Cancer	MCF7	-61.9194
CNS Cancer	U251	8.46619	Breast Cancer	MDA-MB-	-62.7773
			Breast Cancer	HS 578T	58.00374
			Breast Cancer	T-47D	-61.1209
			Breast Cancer	MDA-MB-468	-84.6413

Table 4. Growth inhibition (% control) of compound **49** in the NCI60 cell lines.

PANELNME	CELLNAME	GIPRCNT	PANELNME	CELLNAME	GIPRCNT
Leukemia	CCRF-CEM	26.16653365	Melanoma	LOX IMVI	-46.5487
Leukemia	HL-60(TB)	-43.08739255	Melanoma	MALME-3M	-100
Leukemia	K-562	0.865850512	Melanoma	M14	-91.1652
Leukemia	MOLT-4	26.1993216	Melanoma	MDA-MB-435	-87.4148
Leukemia	RPMI-8226	25.33047339	Melanoma	SK-MEL-2	-16.262
Leukemia	SR	-10.03125	Melanoma	SK-MEL-28	-76.8851
Non-Small Cell Lung	A549/ATCC	-53.26612903	Melanoma	SK-MEL-5	-98.1218
Non-Small Cell Lung	EKVX	27.36687168	Melanoma	UACC-257	-84.4508
Non-Small Cell Lung	HOP-62	-56.63533835	Melanoma	UACC-62	-98.5184
Non-Small Cell Lung	HOP-92	62.4576734	Ovarian Cancer	IGROV1	-13.7639
Non-Small Cell Lung	NCI-H226	-49.1	Ovarian Cancer	OVCAR-3	-1.5625
Non-Small Cell Lung	NCI-H23	-56.52460457	Ovarian Cancer	OVCAR-4	-87.768
Non-Small Cell Lung	NCI-H322M	-96.67388614	Ovarian Cancer	OVCAR-5	-82.2933
Non-Small Cell Lung	NCI-H460	-54.12162162	Ovarian Cancer	OVCAR-8	-15.1765
Non-Small Cell Lung	NCI-H522	-50.54491413	Ovarian Cancer	NCI/ADR-RES	20.14936
Colon Cancer	COLO 205	-68.33964646	Ovarian Cancer	SK-OV-3	-78.6244
Colon Cancer	HCC-2998	-80.83237327	Renal Cancer	786-0	28.12127
Colon Cancer	HCT-116	0.850852918	Renal Cancer	A498	-88.1317
Colon Cancer	HCT-15	-58.80584192	Renal Cancer	ACHN	-35.0589
Colon Cancer	HT29	-21.30829016	Renal Cancer	CAKI-1	-5.26768
Colon Cancer	KM12	9.272487374	Renal Cancer	SN12C	-94.7287
Colon Cancer	SW-620	-37.75201613	Renal Cancer	TK-10	0.122365
CNS Cancer	SF-268	12.4597104	Renal Cancer	UO-31	-99.9594
CNS Cancer	SF-295	-88.88513514	Prostate Cancer	PC-3	11.58377
CNS Cancer	SF-539	-99.3694362	Prostate Cancer	DU-145	-75.9298
CNS Cancer	SNB-19	-81.51574803	Breast Cancer	MCF7	-56.1231
CNS Cancer	SNB-75	-64.69113842	Breast Cancer	MDA-MB-	15.11298
CNS Cancer	U251	-32.64358108	Breast Cancer	HS 578T	-36.5499
			Breast Cancer	BT-549	-93.6913
			Breast Cancer	T-47D	22.46038
			Breast Cancer	MDA-MB-468	-21.9933

Table 5. Growth inhibition (% control) of compound **50** in the NCI60 cell lines.



50

PANELNME	CELLNAME	GIPRCNT	PANELNME	CELLNAME	GIPRCNT
Leukemia	CCRF-CEM	5.712771	Melanoma	LOX IMVI	-50.1492
Leukemia	HL-60(TB)	-50.3957	Melanoma	MALME-3M	-99.1953
Leukemia	K-562	-6.71679	Melanoma	M14	-89.6374
Leukemia	MOLT-4	-36.4229	Melanoma	MDA-MB-435	-91.762
Leukemia	RPMI-8226	27.56721	Melanoma	SK-MEL-2	-34.5495
Leukemia	SR	-27.1607	Melanoma	SK-MEL-28	5.494684
Non-Small Cell Lung Cancer	A549/ATCC	-36.1751	Melanoma	SK-MEL-5	-99.7024
Non-Small Cell Lung Cancer	EKVX	5.132739	Melanoma	UACC-257	-82.2969
Non-Small Cell Lung Cancer	HOP-62	-63.3298	Melanoma	UACC-62	-82.4675
Non-Small Cell Lung Cancer	HOP-92	27.49924	Ovarian Cancer	IGROV1	-32.57
Non-Small Cell Lung Cancer	NCI-H226	-78.8735	Ovarian Cancer	OVCAR-3	-27.9399
Non-Small Cell Lung Cancer	NCI-H23	-39.656	Ovarian Cancer	OVCAR-4	-91.1398
Non-Small Cell Lung Cancer	NCI-H322M	36.62518	Ovarian Cancer	OVCAR-5	-90.4043
Non-Small Cell Lung Cancer	NCI-H460	-56.5637	Ovarian Cancer	OVCAR-8	-10.8526
Non-Small Cell Lung Cancer	NCI-H522	-67.5222	Ovarian Cancer	NCI/ADR-RES	10.14274
Colon Cancer	COLO 205	-94.9856	Ovarian Cancer	SK-OV-3	29.67778
Colon Cancer	HCC-2998	-26.9174	Renal Cancer	786-0	36.68945
Colon Cancer	HCT-116	0.983829	Renal Cancer	A498	-21.1398
Colon Cancer	HCT-15	-47.4718	Renal Cancer	ACHN	-44.1558
Colon Cancer	HT29	-55.5144	Renal Cancer	CAKI-1	33.13822
Colon Cancer	KM12	12.99617	Renal Cancer	RXF 393	38.35717
Colon Cancer	SW-620	4.708827	Renal Cancer	SN12C	-95.418
CNS Cancer	SF-268	1.957085	Renal Cancer	TK-10	80.28756
CNS Cancer	SF-295	-61.5894	Renal Cancer	UO-31	-19.0631
CNS Cancer	SF-539	-52.4375	Prostate Cancer	PC-3	8.007208
CNS Cancer	SNB-19	17.8598	Prostate Cancer	DU-145	-85.7143
CNS Cancer	SNB-75	5.29558	Breast Cancer	MCF7	-57.016
CNS Cancer	U251	0.910837	Breast Cancer	MDA-MB-	-5.99233
			Breast Cancer	HS 578T	-15.9764
			Breast Cancer	BT-549	-97.0139
			Breast Cancer	T-47D	-28.3961
			Breast Cancer	MDA-MB-468	-62.4106

Having now fully described the invention, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully
5 incorporated by reference herein in their entirety.

INCORPORATION BY REFERENCE


The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
10

EQUIVALENTS

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein.
15 Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

What Is Claimed Is:

1. A compound encompassed within Formula I, II or III:



including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof; wherein:

R^1 is selected from the group consisting of hydrogen, or optionally substituted alkyl, or halogen;

R^2 is selected from the group consisting of alkyl, optionally substituted C4-C8 cycloalkyl, optionally substituted C4-C8 heteroalkyl, optionally substituted C4-C8 heterocycloalkyl, optionally substituted C5-C6 aryl, and optionally substituted C4-C6 heteroaryl;


R^{3a} , R^{3b} , R^{3c} , or R^{3d} is selected from the group consisting of hydrogen, halogen, methyl, methoxy, trifluoromethyl, hydroxyl or cyano;

R^4 is selected from the group consisting of alkyl, or heteroalkyl;

A comprises a cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;


X is selected from the group consisting of hydrogen, halogen, amino, heterocycloalkyl, or hydroxyl.

2. The compound of claim 1, wherein said compound is represented by formula IV, or formula V:




or a pharmaceutically acceptable salts or solvates thereof, wherein R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III; wherein n is an integer selected from 0 to 5.

3. The compound of claim 1, wherein said compound is represented in formula VI, or formula VII,




or a pharmaceutically acceptable salts or solvates thereof, wherein R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III; wherein Y is O atom, S atom, or N atom; wherein m is an integer selected from 0 to 9.

4. The compound of claim 1, wherein said compound is represented in formula VIII, and formula IX,




or a pharmaceutically acceptable salts or solvates thereof, wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III.

5. The compound of claim 1, wherein said compound is represented in formula X, or formula XI,




or a pharmaceutically acceptable salts or solvates thereof, wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III.

6. The compound of claim 1, wherein compound is represented in formula XII, or formula XIII,




or a pharmaceutically acceptable salts or solvates thereof, wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III.

7. The compound of claim 1, wherein said compound is represented in formula XIV, or formula XV,



or a pharmaceutically acceptable salts or solvates thereof, wherein R^1 , R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III.


8. The compound of claim 1, wherein said compound is represented in formula XVI, or formula XVII,




or a pharmaceutically acceptable salts or solvates thereof, wherein R^2 , R^{3a} , R^{3b} , R^{3c} , R^{3d} , and X are as defined in connection with formulae I or III; wherein W is independently selected from C atom, or N atom.

9. The compound of any of claims 1-8, wherein R^1 is selected from the group consisting of hydrogen, halo, alkyl, heteroalkyl, optionally substituted C_6 - C_{14} aryl, and optionally substituted 5 to 14 membered heteroaryl.


10. The compound of any of claims 1-8, wherein R^2 is optionally substituted selected from the group consisting of:




11. The compound of any of claims 1-8, wherein R^3 (R^{3a} , R^{3b} , R^{3c} , or R^{3d}) is optionally monosubstituted or polysubstituted selected from the group consisting of:



12. The compound of claim 1, wherein R^4 is optionally substituted selected from the group consisting of:




13. The compound of claim of any of claims 1-8, wherein X is optionally substituted selected from the group consisting of:




14. The compound of claim 1, wherein the compound is selected from the compounds recited in Table 1.

15. A compound selected from the compounds recited in Table 1.


16. A process for preparing the compound of formula **I** by reacting dichloro quinones represented by formula **A** and an arylamines represented by formula **B**,




wherein R^{3a}, R^{3b}, R^{3c}, or R^{3d} is optionally substituted selected from the group consisting of:




17. A process for preparing the compound of formula **II** by reacting nitroaryl represented by formula **C**, arylamines represented by formula **D**, amides represented by formula **E**, and quinones represented by formula **F**,



18. A process for preparing the compound of formula **III** by reacting dichloro quinones represented by formula **A**, and arylamines represented by formula **B**,



wherein R^{3a} , R^{3b} , R^{3c} or R^{3d} is optionally substituted selected from the group consisting of:



19. A pharmaceutical composition comprising a compound of any of claims 1-15.
20. A method of treating, ameliorating, or preventing a hyperproliferative disease in a patient comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of Claim 19.
21. The method of claim 20 wherein said hyperproliferative disease is cancer.
22. The method of claim 21, wherein said cancer is selected from breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma.
23. The method of claim 20 wherein said patient is a human patient.

24. The method of claim 20 further comprising administering to said patient one or more anticancer agents.
25. The method of claim 24 wherein said anticancer agent is a chemotherapeutic agent.
26. The method of claim 24 wherein said anticancer agent is radiation therapy.
27. A kit comprising any of the compounds of Claims 1-15 and instructions for administering said compound to a patient having a hyperproliferative disease.
28. The kit of claim 27 wherein said hyperproliferative disease is cancer.
29. The kit of Claim 28, wherein said cancer is selected from breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma.
30. The kit of claim 27 further comprising one or more anticancer agents.
31. The kit of claim 30, wherein said compound is to be administered together with one or more anticancer agents.

FIG. 1 Growth inhibition (% control) of compound 1 in the NCI60 cell lines.







FIG. 2 Growth inhibition (% control) of compound **13** in the NCI60 cell lines.



FIG. 3 Growth inhibition (% control) of compound **49** in the NCI60 cell lines.



FIG. 4 Growth inhibition (% control) of compound **50** in the NCI60 cell lines.

FIG. 5 Cytotoxicity of compound 13 in the NCI60 cell lines.



National Cancer Institute Developmental Therapeutics Program															
In-Vitro Testing Results															
NSC : D - 809051 / 1			Experiment ID : 1812NS37					Test Type : 00			Units : Molar				
Report Date : January 15, 2019			Test Date : December 03, 2018					QNS :			MC :				
COMI : SH-0403-69			Stain Reagent : SRB Dual-Pass Related					SSPL : 1A11							
Panel/Cell Line	Time	Conc	Log10 Concentration					Percent Growth					GI50	TC50	LC50
			-8.0	-7.0	-6.0	-5.0	-4.0	-3.0	-2.0	-1.0	0.0				
Leukemia															
CCRF-CEM	0.287	1.888	1.720	1.619	1.625	0.317	0.285	102	95	96	2		3.67E-6	5.64E-6	> 1.00E-4
HL-60(TB)	1.050	3.487	3.402	3.432	3.418	0.536	0.460	100	101	100	-45	-58	2.22E-6	4.88E-6	2.38E-6
K-562	0.270	2.711	2.729	2.634	2.515	0.297	0.258	101	97	92	-5	-4	2.72E-6	5.82E-6	> 1.00E-4
NOLM-4	0.684	2.436	2.528	2.452	2.580	0.458	0.452	108	102	98	-31	-32	2.37E-6	5.78E-6	> 1.00E-4
RPWM-8225	0.601	2.083	2.112	2.053	2.081	0.536	0.533	101	96	96	-16	-12	2.69E-6	7.26E-6	> 1.00E-4
SR	0.295	4.223	1.181	1.205	1.161	0.287	0.296	95	96	93	-4	-5	2.75E-6	9.05E-6	> 1.00E-4
Non-Small Cell Lung Cancer															
A549(ATCC)	0.404	2.146	2.081	2.102	2.138	1.734	0.086	96	97	99	79	-84	1.48E-6	3.05E-6	8.16E-6
BEAS	0.838	2.531	2.443	2.337	2.478	0.009	0.004	95	97	-89	-100		1.75E-6	3.17E-6	5.80E-6
HOP-62	0.733	2.074	1.965	1.934	1.927	0.580	0.025	92	90	88	19	-87	3.63E-6	1.47E-6	1.30E-6
HOP-82	1.110	1.821	1.786	1.649	1.842	0.137	0.158	83	66	60	-86	-88	1.68E-6	3.21E-6	6.13E-6
NCI-H320	0.827	2.361	2.112	2.106	2.119	0.134	0.021	93	93	94	-84	-88	1.77E-6	3.58E-6	6.48E-6
NCI-H323	0.754	2.628	2.543	2.560	2.430	0.258	0.214	95	93	89	-66	-73	1.79E-6	3.75E-6	7.83E-6
NCI-H322M	0.842	2.158	2.034	2.015	2.050	0.040	0.001	90	88	84	-91	-100	1.64E-6	3.00E-6	5.34E-6
NCI-H460	0.179	1.747	1.795	1.720	1.887	0.416	0.068	102	98	97	75	-62	2.74E-6	1.57E-6	8.94E-6
NCI-H522	0.588	2.040	1.896	1.910	1.793	0.350	0.265	97	81	83	-39	-38	1.86E-6	4.78E-6	> 1.00E-4
Colon Cancer															
COLO-205	0.347	1.324	1.334	1.288	1.289	0.032	0.041	101	96	96	-91	-95	1.77E-6	3.27E-6	9.56E-6
HCC-2998	0.844	2.286	2.257	2.198	2.195	1.584	0.104	96	94	94	27	-84	4.54E-6	1.75E-6	4.54E-6
HCT-116	0.208	2.387	2.204	2.220	2.090	0.025	0.017	96	96	90	-86	-90	1.67E-6	3.19E-6	6.10E-6
HCT-15	0.378	2.945	2.866	2.828	2.593	0.146	0.105	97	95	90	-82	-72	1.84E-6	3.63E-6	8.40E-6
HT29	0.242	2.116	2.083	2.128	2.083	0.136	0.180	97	100	98	-44	-28	2.19E-6	4.02E-6	> 1.00E-4
KM12	0.542	2.724	2.690	2.684	2.680	1.654	0.068	96	98	96	51	-87	1.62E-6	2.35E-6	5.37E-6
SW-620	0.228	1.823	1.770	1.717	1.710	0.117	0.140	97	93	93	-49	-38	2.61E-6	4.52E-6	> 1.00E-4
CNS Cancer															
SF-268	0.812	2.686	2.490	2.424	2.570	0.352	0.210	98	93	91	-57	-74	1.88E-6	4.13E-6	9.01E-6
SF-295	1.052	3.280	3.176	3.209	3.247	3.251	0.031	97	98	101	101	-97	1.80E-6	3.23E-6	5.78E-6
SF-539	0.852	2.771	2.728	2.646	2.809	0.098	0.005	98	93	95	-52	-59	1.74E-6	3.22E-6	5.86E-6
SW63-19	0.610	2.162	2.097	2.060	2.123	1.368	0.022	98	93	97	-89	-95	9.49E-6	2.17E-6	4.79E-6
SW63-78	1.105	1.684	1.687	1.682	1.741	1.682	0.066	71	87	77	-8	-95	2.11E-6	8.53E-6	3.18E-6
U251	0.575	1.772	1.717	1.717	1.772	0.006	0.013	96	96	100	-59	-57	1.76E-6	3.16E-6	5.70E-6
Melanoma															
LDX-MV1	0.634	3.344	3.316	3.288	3.307	0.027	0.027	96	98	98	-86	-86	1.78E-6	3.27E-6	5.82E-6
MEL-ME-3M	0.713	1.651	1.582	1.523	1.532	0.010	0.003	93	88	88	-39	-100	1.52E-6	2.59E-6	5.51E-6
M14	0.470	2.162	2.081	2.053	2.181	0.034	0.024	95	96	101	-93	-93	1.84E-6	3.20E-6	6.02E-6
MDA-MB-435	0.525	2.887	2.690	2.602	2.852	0.097	0.057	100	100	102	-97	-89	1.68E-6	3.48E-6	6.34E-6
SK-MEL-2	0.788	2.139	2.131	2.179	2.115	0.157	0.109	99	103	98	-80	-88	1.87E-6	3.58E-6	6.78E-6
SK-MEL-29	0.825	2.382	2.405	2.425	2.480	0.013	0.009	101	103	105	-96	-98	1.88E-6	3.31E-6	5.82E-6
SK-MEL-5	0.898	3.170	3.089	3.057	3.083	0.098	0.013	97	95	98	-99	-99	1.72E-6	3.10E-6	5.28E-6
UACC-257	0.886	2.136	2.116	2.055	2.052	0.029	0.003	98	94	94	-97	-97	1.70E-6	3.11E-6	5.93E-6
UACC-52	1.044	2.956	2.882	2.879	2.887	0.034	0.016	96	95	95	-97	-98	1.71E-6	3.12E-6	5.70E-6
Ovarian Cancer															
IGROV1	0.458	2.013	1.995	2.020	1.976	0.194	0.108	96	100	98	-75	-78	1.67E-6	3.59E-6	6.92E-6
OVCAR-3	0.437	1.821	1.576	1.501	1.473	0.048	0.049	96	92	87	-84	-83	1.63E-6	3.13E-6	6.01E-6
OVCAR-4	0.718	1.520	1.454	1.455	1.385	0.029	0.023	92	86	81	-86	-57	1.50E-6	2.57E-6	5.50E-6
OVCAR-5	0.610	1.364	1.345	1.348	1.385	0.022	0.014	94	94	95	-88	-58	1.80E-6	3.34E-6	6.75E-6
OVCAR-8	0.453	2.178	2.157	2.173	2.186	0.030	0.079	96	100	101	-99	-83	1.85E-6	3.40E-6	6.23E-6
NOVADR-RES	0.650	2.316	2.326	2.309	2.323	0.673	0.479	101	100	100	-8	-31	3.88E-6	9.46E-6	> 1.00E-4
SK-OV-3	0.682	1.702	1.695	1.620	1.622	1.452	0.909	95	90	90	-99	-98	1.30E-6	2.38E-6	5.12E-6
Renal Cancer															
786-O	0.657	2.612	2.462	2.333	2.503	0.010	0.017	94	86	95	-98	-97	1.71E-6	3.10E-6	5.62E-6
A498	1.420	2.181	2.021	1.850	1.957	1.878	0.927	98	85	75	-98	-95	1.28E-6	2.56E-6	5.13E-6
ACHN	0.342	1.387	1.419	1.351	1.308	0.002	-0.003	93	95	98	-100	-100	1.75E-6	3.13E-6	5.69E-6
CAKI-1	0.503	1.746	1.613	1.619	1.652	0.014	0.016	90	85	93	-97	-95	1.65E-6	3.06E-6	5.64E-6
RJF-353	0.641	1.652	1.631	1.626	1.530	0.014	0.006	97	97	92	-98	-94	1.67E-6	3.05E-6	5.78E-6
SN12C	0.671	1.672	2.012	2.574	2.587	0.007	-0.009	97	95	96	-99	-100	1.72E-6	3.15E-6	5.60E-6
TK-10	0.647	1.788	1.689	1.741	1.816	0.030	0.004	91	98	103	-85	-80	1.95E-6	3.42E-6	6.00E-6
UO-31	0.730	1.817	1.710	1.770	1.803	0.006	-0.009	83	88	90	-100	-100	1.63E-6	2.98E-6	5.46E-6
Prostate Cancer															
PC-3	0.434	1.736	1.657	1.615	1.525	0.077	0.045	94	91	82	-82	-90	1.67E-6	3.16E-6	6.37E-6
DU-145	0.418	1.865	1.904	1.824	1.814	0.033	0.003	103	97	97	-82	-82	1.76E-6	3.25E-6	5.88E-6
Breast Cancer															
MCF7	0.458	2.364	2.186	2.135	2.135	0.282	0.262	96	88	88	-95	-50	2.64E-6	5.17E-6	6.82E-6
MDA-MB-231(ATCC)	0.650	1.558	1.528	1.455	1.430	0.047	0.071	99	90	94	-95	-60	1.73E-6	3.19E-6	5.88E-6
HS 578T	1.143	2.324	2.252	2.211	2.214	0.095	1.107	95	90	91	-13	-3	2.47E-6	7.49E-6	> 1.00E-4
T-549	0.758	1.917	1.799	1.802	1.785	0.097	0.009	99	90	85	-99	-98	1.61E-6	2.97E-6	5.82E-6
T-47D	0.676	2.284	2.204	2.085	1.982	0.345	0.501	93	83	75	-65	-48	1.54E-6	3.48E-6	5.82E-6
MDA-MB-468	1.050	2.482	2.326	2.311	2.108	0.217	0.308	95	93	78	-79	-82	1.51E-6	3.13E-6	6.61E-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/21444

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/164; A61K 31/18; C07C 229/10 (2020.01)

CPC - A61K 31/18; C07C 225/20; C07C 229/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2017/0283374 A1 (Pellficure Pharmaceuticals, Inc) 05 October 2017 (05.10.2017); para [0190]	1-2, (9, 11)/(1-2)
A	WO 2017/155991 A1 (THE REGENTS OF THE UNIVERSITY OF MICHIGAN) 14 September 2017 (14.09.2017); pg. 25	1-2, (9, 11)/(1-2)
A	Gopinath et al. "Switching Futile para -Quinone to Efficient Reactive Oxygen Species Generator: Ubiquitin-Specific Protease-2 Inhibition, Electrocatalysis, and Quantification" ChemBioChem. 22 June 2017 (22.06.2017) vol 18, pg. 1683-1687; pg. 1684, Scheme 1	1-2, (9, 11)/(1-2)
A	WO 1997/021432 A1 (LABORATOIRE INNOTHERA, S.A.) 19 June 1997 (19.06.1997); entire document	1-2, (9, 11)/(1-2)
A	US 2018/0116977 A1 (Pellficure Pharmaceuticals, Inc) 03 May 2018 (03.05.2018); entire document	1-2, (9, 11)/(1-2)

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 June 2020

Date of mailing of the international search report

06 JUL 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/21444

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 19-31
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(see supplemental page)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-2 and (9, 11)/(1-2)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 20/21444

--continued from supplemental page--

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-15, directed to a compound of claim 1, formula I, II or III. The compound of claim 1 will be searched to the extent that it encompasses the first species of claim 1, represented by a compound of formula I wherein R1 is hydrogen; R2 is alkyl; R3a, R3b, R3c and R3d are hydrogen; A is cycloalkyl; X is hydrogen. It is believed that claims 1-2 and (9, 11)/(1-2) read on this first named invention, and thus these claims will be searched without fee. Applicant is invited to elect additional compounds of claim 1, wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the '+' group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of formula I wherein R1 is hydrogen; R2 is alkyl; R3a, R3b, R3c and R3d are hydrogen; A is heterocycloalkyl; X is hydrogen (i.e., claims 1, 3 and (9, 11)/(1, 3)).

Group II: Claims 16-18, directed to a process for preparing the compound of formula I/II/III by reacting A and B / C->D->E->F / A and B.

The group of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound of formula I, II or III, which is not required by any other invention of Group I+ or II.

Group II includes the technical feature of a process for preparing the compound of formula I/II/III by reacting A and B / C->D->E->F / A and B, which is not required by any other invention of Group I+.

Common technical features:

The inventions of Groups I+ share the technical feature of a compound of formula I, II or III.

The inventions of Groups I+ and II share the technical feature of a compound of formula I, II or III.

These shared technical features, however, do not provide a contribution over the prior art, as being anticipated by US 2017/0283374 A1 to Pellficure Pharmaceuticals, Inc (hereinafter Pellficure). Pellficure discloses a compound of formula I wherein R1 is hydrogen; R2 is alkyl; R3a, R3b, R3c and R3d are hydrogen; A is aryl; X is hydrogen (para [0190]: (pg. 38) Table 1: compound F60).

As said compound was known in the art at the time of the invention, these cannot be considered special technical features that would otherwise unify the inventions of Groups I+ or II. The inventions of Group I+ and II thus lack unity under PCT Rule 13.

Note: Claims 19-31 have been found to be unsearchable because they are not drafted in accordance with the second and third sentences of Rule 6.4(a).